<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:_3="http://edrn.nci.nih.gov/rdf/schema.rdf#"
   xmlns:_4="http://purl.org/dc/terms/"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/239">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:dataSharingPlan>We propose that the EDRN U of M Biomarker development lab provide detailed protocols for
urine collection to each of the participating EDRN sites. The preserved sediments and whole urine will be sent to the U of M site in a blinded fashion. The U of M EDRN site will then run the multiplex urine test on the urines from each site and provide the coded data to the central EDRN DMCC site for statistical analyses (Dr. Zideng).</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:objective>The goal of this EDRN set-asides proposal is to carry out pre-validation studies on
sarcosine as a metabolomic biomarker of prostate cancer in urine. Not only does sarcosine have potential as a marker for the early detection of prostate cancer in post-DRE urine specimens-- but since its highest levels are in metastatic disease it might have utility in predicting aggressiveness of clinically localized disease. We will also use these funds to determine if we can add additional metabolites to sarcosine in
order to develop a multiplex metabolomic biomarker panel in prostate cancer. In addition to sarcosine, we have 10-12 additional candidate metabolomic biomarkers that could be developed (as seen from our preliminary global metabolite studies).</_3:objective>
    <_3:startDate>May  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:estimatedFinishDate>Apr 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_4:title>EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:fieldOfResearch>Metabolomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/305">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/538"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/538"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>BRSCW Reference Set: Biosite</_3:abbreviatedName>
    <_4:title>BRSCW Applicant:  Buechler - Biosite Inc (2009)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/246">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/448"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/448"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer</_3:abbreviatedName>
    <_3:startDate>Jul  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/448"/>
    <_4:title>Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:plannedSampleSize>A pooled serum sample from at least 20 individuals that are biopsy-positive and a pooled serum sample from at least 20 patients that are biopsy-negative.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/312">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>118 cases, 474 controls</_3:finalSampleSize>
    <_3:dataSharingPlan>Share within EDRN and public after publication</_3:dataSharingPlan>
    <_3:secureOutcome>Results will be released after publication</_3:secureOutcome>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Based on the phase II results, the PLCO provided the phase III proximate samples to the assay sites.  Investigators were also asked to provide their algorithm or rule for combining various markers to determine whether a panel of markers might perform better than a single marker.  Using a pre-specified data analysis plan that involved three steps, each site first submitted an algorithm based on the phase II results, which was evaluated by the PLCO statistician.  Then the training half of the phase III dataset was unblinded for further algorithm development and was validated in the remaining half of the dataset.  </_3:analyticMethod>
    <_3:estimatedFinishDate>Jan  5 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:objective>Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study.  Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.  </_3:objective>
    <_3:bmName>  APO  
  B2M  
  B7-H4
  CA125 
  CA15.3
  CA19.9
  CA72.4
  CTAP-III  
  EGFR
  Eotaxin
  HE4
  HEPC  
  IGF2
  IGFBP2
  ITIH4  
  KLK6 
  Leptin
  Mesothelin
  MIF
  MMP3
  MMP7
  OPN
  Prolactin
  SLPI
  Spondin-2
  sV CAM
  Transferrin
  Transthyretin</_3:bmName>
    <_3:phasedStatus>3</_3:phasedStatus>
    <_3:eligibilityCriteria>borderline ovarian cancers were excluded
postmenopausal women only</_3:eligibilityCriteria>
    <_3:startDate>Oct 21 2008 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_4:description>Although many early detection biomarkers for ovarian cancer are described, few studies used samples collected from asymptomatic women.  This study was a coordinated validation effort by six research teams to evaluate panels of biomarkers for ovarian cancer in pre-clinical specimens from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial.  Thirty-five markers previously examined in a phase II study were evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls.  A panel constructed using logistic regression combining markers from all sites was evaluated.  Most of the best performing markers in phase 2 specimens had similar or better sensitivity when moving to the phase III PLCO specimens.  Performance of all markers declined in phase III specimens more remote than 6 months from diagnosis.  Analyses are currently being conducted to identify a panel of markers that may better identify cases than CA125 alone.</_4:description>
    <_3:blinding>all samples obtained from PLCO are blinded</_3:blinding>
    <_3:aims>1). Using 1 ml of sera from the PLCO subjects, apply the panel of markers identified through the phase II study to all prediagnostic  specimens from all PLCO participants who subsequently developed ovarian cancer and from all longitudinal specimens from 10 matched controls who did not develop ovarian cancer for each case.
2). Using any residual sera, apply high end mass spectrometry and other discovery techniques to seek new markers especially in pre-clinical cases who were false negative or controls who were false positive by the panels. 
</_3:aims>
    <_3:outcome>Results will be released after publication</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/531"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/235"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/236"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/231"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>PLCO Ovarian Phase III Validation Study</_4:title>
    <_3:abbreviatedName>OVAR-VAL-PLCO</_3:abbreviatedName>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/112">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Proteomics/SNPs</_3:abbreviatedName>
    <_4:title>Detection of Serum Proteomic Patterns and SNPs in Breast Cancer: A Pilot Study</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/103">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer</_3:abbreviatedName>
    <_4:title>Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/255">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/446"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Development and Clinical Validation of Biomarkers for Prostate Cancer</_3:abbreviatedName>
    <_3:startDate>Jul  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_4:title>Development and Clinical Validation of Biomarkers for Prostate Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/267">
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/509"/>
    <_3:objective> To evaluate biomarker performance in an out-side cohort of LC and HCC patients </_3:objective>
    <_3:design>Case/control</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/509"/>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/134"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Liver Reference Set (Rapid) Giannelli</_3:abbreviatedName>
    <_3:startDate>Oct 13 2008 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:bmName>GP73</_3:bmName>
    <_3:finalSampleSize>50 HCC Liver Cancer Cases and 50 Cirrhotic Controls</_3:finalSampleSize>
    <_3:cancerType>                                                                                                    </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:blinding>All samples were blinded as collected through the DCP validation study</_3:blinding>
    <_3:aims>To evaluate biomarker performanceof SCCA, SCCA-IC, AFP-IC and PIVKA-II versus AFP  in an out-side cohort of LC and HCC patients. Our hypothesis is that the performance of the investigated biomarkers is affected by the accuracy of patient criteria inclusion, and  potential inaccuracy of serum storage. Therefore, the study  we have already reported in the literature is not yet clear cut and conclusive, nevertheless, the data seem promising to be further investigated. Our goals is to clinically validate proposed biomarkers in an external sample population, with more stringent criteria of selection and of data analysis.
The performance of each marker will be evaluate through a ROC (Receiving Operating Charachteristic) analysis determining the area under the ROC curve, sensitivity and specificity. A multivariate logistic model will be also carried out to evaluate the performance of combination of marker.
</_3:aims>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_4:title>Liver Cancer Specimen Reference Set Application (Rapid): Giannelli - Univ of Bari (2008)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:estimatedFinishDate>Dec 13 2008 12:00AM</_3:estimatedFinishDate>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/27">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias</_3:abbreviatedName>
    <_4:title>Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias Using a Stool Based DNA Analysis</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/243">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>Sera from 200 patients with nonmalignant head and neck diseases; Sera from 200 patients with autoimmune diseases; Sera from 500 HNSCC patients (200 early stage and 300 late stage); Sera from 500 control patients</_3:finalSampleSize>
    <_3:dataSharingPlan>As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.</_3:analyticMethod>
    <_3:abbreviatedName>Proteomic Approach for Diagnostic Applications in Head and Neck Cancer</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:estimatedFinishDate>Mar 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>Autoantibodies</_3:bmName>
    <_3:startDate>Apr  1 2007 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>N/A</_3:blinding>
    <_3:aims>AIM 1:  Eliminate nonspecific antigen biomarkers that cross-react with sera from patients with nonmalignant head and neck diseases, autoimmune diseases and other types of cancers.
AIM 2:  Validate this diagnostic strategy for early HNSCC detection based on pattern of serum immunoreactivity against the biomarker panel.
AIM 3:  Assess the use of this diagnostic strategy for early detection of HNSCC in collaboration with other EDRN and non-EDRN sites.
</_3:aims>
    <_3:outcome>We have demonstrated the feasibility of cancer detection based on analysis of patterns of serum immunoreactivity against a panel of cancer biomarkers selected using microarray-based serological profiling and specialized bioinformatics.  Combining phage display technology with protein microarray, we screened 5,133 selectively cloned tumor antigens and ranked them using a feature selection method based on receiver-operator characteristic curves for neural network classifiers.  A model, built using the top-ranked 40 biomarkers, was validated by bootstrapping on an independent set of 80 cancer and 78 control sera.  Estimated accuracy of this modeling strategy was 83% (95% CI 77-88) with sensitivity of 83% (95% CI 74-92) and specificity of 83% (95% CI 75-94).</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Proteomic Approach for Diagnostic Applications in Head and Neck Cancer</_4:title>
    <_3:objective>To evaluate the test characteristics of a panel of biomarkers for identifying patients with early stage head and neck squamous cell carcinoma (HNSCC). The primary endpoints are sensitivity, specificity and accuracy of the marker panel. This study of the test characteristics of a modeling strategy for diagnosing HNSCC uses a case-control design, with several types of cases and several types of controls.</_3:objective>
    <_3:cancerType>144, 143, 148, 140, 160, 147, 146, 149, 145, 141                                                    </_3:cancerType>
    <_3:plannedSampleSize>Sera from 200 patients with nonmalignant head and neck diseases
Sera from 200 patients with autoimmune diseases
Sera from 300 patients with other types of cancer
Sera from 500 HNSCC patients (200 early stage and 300 late stage)
Sera from 500 control patients</_3:plannedSampleSize>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/102">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Breast Ductal  Lavage Fluid Specimen Bank</_3:abbreviatedName>
    <_4:title>Breast Ductal  Lavage Fluid Specimen Bank</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/127">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:abbreviatedName>PROS-RAPID</_3:abbreviatedName>
    <_3:finishDate>Feb  7 2007 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:estimatedFinishDate>Feb 10 2007 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:bmName>hk2, hk4, hk11, TSP-1, %fPSA, -2ProPSA</_3:bmName>
    <_3:dataSharingPlan>Data to be shared with collaborative group members in order to decide which markers move forward.</_3:dataSharingPlan>
    <_3:startDate>Feb  1 2006 12:00AM</_3:startDate>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:blinding>Specimen shipped to Dan Chan reference lab for aliquoting, re-labeling (blinding done by NCI), and shipping to four labs. </_3:blinding>
    <_3:aims>Test candidate prostate markers at various labs using specimens collected and processed in a similar manner.</_3:aims>
    <_3:outcome>hK2, hK4 and hK11 do not distinguish cases from controls. TSP-1 does not seem to distinguish cases from controls. %free PSA has some value: at 0-10% free PSA range for men whose PSA between 4-10 ng/ml, this cutoff point picks up near three folds cases as controls and has since moved on to validation.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/161"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/292"/>
    <_4:title>Prostate Rapid Pre-Validation Set</_4:title>
    <_3:objective>Determine which markers move to validation using the prospectie prostate reference set samples.</_3:objective>
    <_3:finalSampleSize>63 Prostate Cancer Cases0, 60 non-malignant</_3:finalSampleSize>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/201">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>N=20-30</_3:finalSampleSize>
    <_3:dataSharingPlan>All high dimensional data (genomics and proteomics)are available for query and download from our NIDDK-sponsored public database UESC, which is also linked to the EDRN site.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Genomic (Affymetrix GeneChip) analysis of sorted cancer cells and their normal counterpart (CD26+ prostate cancer vs. CD26+ luminal; CD90+ tumor-associated stromal vs. CD49a+ stromal; CD9+ bladder cancer vs. CD9+ superficial urothelial) to identify up-regulated genes encoding secreted or extracellular proteins.

Proteomic analysis based on mass spectrometry to measure urinary levels of the protein candidates identified. </_3:analyticMethod>
    <_3:abbreviatedName>Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>CD90</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/518"/>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_4:description>Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.</_4:description>
    <_3:startDate>Jan  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>n/a</_3:blinding>
    <_3:aims>To develop multiple reaction monitoring (MRM) proteomics to measure CD90 in urine samples of pre-op(erative) prostate cancer, biopsy negative, post-op, pre-op bladder cancer, and non-cancer. MRM uses triple quadrupole mass spectrometer and synthetic isotopically labeled CD90 signature peptides for detection at the fmol level.</_3:aims>
    <_3:outcome>Our first MRM proteomics found differences in CD90 levels among pre-op, biopsy negative, post-op and non-cancer urine samples. The measured amounts ranged from 0.01173 fmol in non-cancer to 1.987284 fmol in pre-op.

Overexpression of CD90 is characteristic of all tumors, including those in the transition zone, and regardless of Gleason grades.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection</_4:title>
    <_3:objective>CD90/THY1 is overexpressed by tumor-associated stromal cells as scored by immunohistochemistry, RT-PCR analysis of laser-capture microdissected cells. CD90 protein is detected by quantitative glycopeptide-capture proteomics in tissue digestion media preparations, and also by Western blotting. CD90 protein is detected in urine. The goal is to determine if urinary CD90 level can be used to detect cancer.</_3:objective>
    <_3:comments>Since CD90 is expressed by many other cell types (e.g., T cells), its prostate cancer specificity as a urinary marker needs to be rigorously tested. </_3:comments>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>No specified sample size for this protocol.  Study will use urine specimens.</_3:plannedSampleSize>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/311">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/260"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/260"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Liver Ref Set: Lubman (Rapid #1) - Univ of Mich</_3:abbreviatedName>
    <_4:title>Liver Reference Set Applicant (Rapid #1): Lubman - Univ of Michigan</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/292">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/455"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:design>Convenience</_3:design>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/455"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Prostate Rapid Reference Set: Getzenberg (2006)</_3:abbreviatedName>
    <_4:title>Prostate Rapid Reference Set: Getzenberg - Johns Hopkins (2006)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:dataSharingPlan>eCAS through EKE</_3:dataSharingPlan>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/108">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Data will be shared after Cangen submits to FDA and receives response from FDA.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/121"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>MSA</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Oct  1 2007 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>D4S243, D21S1245, FGA, D17S695, D16S476, D9S171, IFN-A, D20S48, D17S654, D16S310, THO1, D9SS162, D9S747, MBP and MBPA</_3:bmName>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:startDate>Oct  1 2003 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>Analysis Labs only have specimen IDs with no relationship to study group</_3:blinding>
    <_3:aims>Aim 1: This study will test the specificity of MSA in two groups of participants without bladder cancer&amp;#9472;both healthy, normal controls as well as participants without bladder cancer who have conditions known to confound the performance of previous urinary tests for bladder cancer.
Aim 2: This study will test the sensitivity of MSA in the presence of clinically evident, pathologically confirmed bladder cancer.
Aim 3: This study will test the sensitivity and specificity of MSA for the detection of bladder cancer among participants undergoing surveillance for bladder cancer.
Aim 4: This study will test the value of MSA to predict subsequent development of bladder cancer among participants with a history of bladder cancer.
</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/310"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/124"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/120"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/226"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/222"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/121"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/116"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/221"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/287"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/280"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/110"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/125"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/288"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/114"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/299"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/112"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/201"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/228"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/223"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/136"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/298"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/119"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/115"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/227"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/122"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/117"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/111"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/118"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>Detection of Bladder CA by Microsatellite Analysis (MSA)</_4:title>
    <_3:objective>Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting bladder cancer in participants requiring cystoscopy.  This technique will be compared to the diagnostic standard of cystoscopy, as well as to urine cytology.
Goal 2: To determine the temporal performance characteristics of microsatellite analysis of urine sediment.
Goal 3: To determine which of the 15 individual markers or combination of markers that make up the MSA test are most predictive of the presence of bladder cancer.
</_3:objective>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>300 incident or recurrent superficial bladder cancer cases, 100 healthy controls, 25 BPH controls, 25 foreign body controls, 25 GU infection controls and 25 hematuria controls.</_3:plannedSampleSize>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/244">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/238"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/266"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/449"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/457"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/450"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/452"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/453"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/266"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Ovarian Validation Study - Mor</_3:abbreviatedName>
    <_3:startDate>May  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Nov  1 2008 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Phase II Validation of a New Panel of Biomarkers for Early Detection of Ovarian Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:plannedSampleSize>Sera from 500 participants with confirmed ovarian cancer
Sera from 200 normal, healthy participants
Sera from 200 participants with benign disease or who are high risk</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/59">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>CLUE Studies: Evaluating Biomarkers of Carcinogenesis</_3:abbreviatedName>
    <_4:title>CLUE Studies: Evaluating Biomarkers of Carcinogenesis</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174, 162, 172                                                                                       </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/76">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Body Fluids as a Source of Diagnostic Biomarkers</_3:abbreviatedName>
    <_3:startDate>Nov  1 1999 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174, 185                                                                                            </_3:cancerType>
    <_3:estimatedFinishDate>Oct  1 2009 12:00AM</_3:estimatedFinishDate>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_4:title>Body Fluids as a Source of Diagnostic Biomarkers</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>1200 prostate cancer cases; 750 benign or other urologic malignancies
50-60 breast cancer cases and 50-60 benign controls per year.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/248">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/283"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/283"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/251"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008)</_3:abbreviatedName>
    <_4:title>Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/283"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/288">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/118"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>BRSCW Applicant: Lokshin (2008)</_3:abbreviatedName>
    <_3:startDate>Mar 14 2008 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Mar 13 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>BRSCW Application: Lokshin - Univ of Pitts (2008)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/99">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Detection of cancer DNA markers in urine</_3:abbreviatedName>
    <_4:title>Detection of cancer DNA markers in urine</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153, 154                                                                                            </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/250">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/455"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/455"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/251"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008)</_3:abbreviatedName>
    <_4:title>Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/455"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>Serum samples from 60 participants with colorectal adenocarcinoma, 60 with colorectal adenomas, 60 with hyperplastic polyps, 30 with inflammatory bowel conditions, and 60 with endoscopically normal colons.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/240">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Molecular Progression of Methylation in Bladder Cancer</_3:abbreviatedName>
    <_3:startDate>Feb  1 2005 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jan 31 2006 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_4:title>Molecular Progression of Methylation in Bladder Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/52">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>SABOR</_3:abbreviatedName>
    <_3:startDate>Jan  1 2000 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Feb 28 2010 12:00AM</_3:estimatedFinishDate>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_4:title>San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>9000 healthy men</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/58">
    <_3:design>Registry</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_4:title>The Biomarker Knowledge System Informatics Pilot Project Supplement To The Biomarker Development Laboratory at Moffitt (Bedlam)</_4:title>
    <_3:abbreviatedName>Pilot Project Supplement To BEDLAM</_3:abbreviatedName>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>The Biomarker Knowledge System Informatics Pilot Project goal will develop network interfaces among databases that contain information about existing clinical populations and biospecimens and data relating to those specimens that are important in biomarker assay validation.  This protocol comprises one of two that will comprise the Moffitt participation in the Biomarker Knowledge System Informatics Pilot Project.   THIS PROTOCOL (58) is the Sput-Epi Database.</_4:description>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/105">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Ecogenetic Study of Lung Cancer</_3:abbreviatedName>
    <_4:title>Ecogenetic Study of Lung Cancer</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/237">
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:abbreviatedName>High-Throughput Evaluation of Breast Cancer Markers</_3:abbreviatedName>
    <_3:finishDate>Jul 31 2010 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>High mass accuracy LC-MS proteomics and ELISA microarrays.</_3:analyticMethod>
    <_3:estimatedFinishDate>Sep 30 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:bmName>amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1alpha and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor alpha, tissue necrosis factor alpha, urokinase plasminogen activator, vascular endothelial growth factor</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1287"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/848"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1292"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1286"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/849"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1289"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1293"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1294"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1288"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1290"/>
    <_3:startDate>Oct  1 2005 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:aims>Aim #1.  Identify new candidate biomarkers of breast cancer by using a semi-quantitative proteomic analysis of plasma.  This analysis will employ capillary liquid chromatography (cLC) interfaced with Fourier transform ion cyclotron resonance (FTICR) mass spectrometry (MS), which is an exceptionally sensitive method for measuring peptides.  We are independently developing a database of proteins secreted into nipple aspirate fluid (NAF) from women with or without breast cancer.  This database will allow us to identify proteins in plasma that are produced by the breast, thereby allowing selection of proteins that are more likely to be specific markers for breast disease.  Because some proteins may only be useful for detecting a single breast cancer subtype, we will analyze 20 samples/group from four groups of women: 1) healthy women, 2) women with ductal carcinoma in situ (DCIS; stage 0), 3) early ductal cancer (stages 1+2), and 4) early lobular cancer (stages 1+2).

Aim #2.  Develop an enzyme-linked immunosorbent assay (ELISA) microarray chip that can simultaneously assay ~50 proteins that are potential markers for non-invasive breast cancer.  These proteins will be selected based on the results of Aim #1, guidance from the EDRN Steering Committee, published reports and other defined criteria.  Where possible, commercial antigen and antibody reagents will be used for these analyses.  However, it is anticipated that a major effort will be required for the development and validation of reagents for many of the ELISA assays.  

Aim #3.  Determine whether the quantitative analysis of 25 proteins by ELISA microarray can distinguish between plasma samples from women with or without breast cancer.  A set of 1000 plasma samples, approximately equally divided between women with and without breast cancer, will be obtained from the Army?s CBCP.  This is an exceptionally high-quality set of samples that was collected under well-defined clinical protocols with an extensive set of epidemiological data.  The epidemiological information will be used to evaluate the influence of factors other than breast cancer on individual protein levels, with the goal of accounting for predictable variability in marker levels.  Profile analysis of the potential cancer markers will then be undertaken.  For this analysis, the samples will be evenly split into a ?training? set and a ?validation? set of samples, with each set having equal numbers of samples from the control and cancer groups.
</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>High-Throughput Evaluation of Breast Cancer Markers</_4:title>
    <_3:objective>The objective of this study is to use a combination of AMT proteomics and ELISA microarray testing to discover and validate novel biomarkers for breast cancer.</_3:objective>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>1000 plasma samples, approximately equally divided between women with and without breast cancer</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/80">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>MMR protein expression in HNPCC</_3:abbreviatedName>
    <_4:title>MMR protein expression in HNPCC</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/65">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:design>Registry</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Hereditary Cancer Institute family study specimen bank</_3:abbreviatedName>
    <_4:title>Hereditary Cancer Institute family study specimen bank</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/54">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Validation of the Mutagen Sensitivity and Chromosomal Hotspot Assays</_3:abbreviatedName>
    <_4:title>Validation of the Mutagen Sensitivity and Chromosomal Hotspot Assays</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/63"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/109">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Data to be shared upon publication.</_3:dataSharingPlan>
    <_3:finishDate>Feb  1 2005 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The criteria for agreement among labs is based on the agreement in mass location and agreement in protein intensity. Since the true protein mass is unknown at each protein mass measured from the machine (there is always some measurement error, no matter how small it is), the mass location agreement is determined by the agreement of the locations of peaks between each lab and the reference lab (EVMS) and between each lab and other four labs combined. More specifically, after peak identification and alignment are performed by each lab, the coefficient of variation (CV) and intra-class correlation coefficient (ICC) for peak location measures and for peak intensity measures will be calculated for each peak location.  The between-lab variation will be compared to the between-sample variation. </_3:analyticMethod>
    <_3:abbreviatedName>SELDI -I</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Dec 23 2003 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>protein</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/524"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:startDate>Dec 23 2002 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>n/a pooled serum</_3:blinding>
    <_3:aims>Specific Aim IA/Phase IA - The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC).

Specific Aim IB/Phase IB - The EPSIC will synchronize SELDI output at the seven participating institutions using prostate cancer/control samples with verified presence of optimized diagnostic peaks. The reproducibility of QSTAR&amp;#61668; will also be determined using the same samples and compared to that of the PBS-II data.

Specific Aim IC/Phase IC - The EPSIC will implement a seven-center collaboration to synchronize SELDI output using a new and expanded cohort of prostate cancer cases and controls obtained from all sites. The reproducibility of QSTAR&amp;#61668; will also be determined using the same samples and compared to that of the PBS-II data.

</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/127"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/108"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/93"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>SELDI Phase I:  Assay Validation-Prostate</_4:title>
    <_3:objective>It is then the goal of this collaborative project ? EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) - to use state-of-the-art protein profiling technology to develop and validate such screening methods</_3:objective>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC).  The target was to recruit 100 healthy males and 100 healthy females to donate two tubes of blood.  Pregnant women and subjects less than 110 pounds were excluded from the blood collection.  An IRB protocol was submitted two months in advance of the project.  After IRB approval, fliers were generated and posted at many locations (e.g., EVMS, hospitals, doctor?s offices).  The blood was collected on November 6, 2002 from 7:30 am to 2:00 pm. A total of 360 healthy people (154 male and 206 female) donated two tubes of blood each to make quality control (QC) serum</_3:plannedSampleSize>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/287">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Prostate Rapid Ref Set: Diamandis (2006)</_3:abbreviatedName>
    <_3:startDate>Feb  1 2006 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Feb  7 2007 12:00AM</_3:estimatedFinishDate>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:bmName>hK2, hK4 and hK11</_3:bmName>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/192">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>
</_3:finalSampleSize>
    <_3:dataSharingPlan>Primary data is shared between the two EDRN sites immediately.  The results will be presented at EDRN meetings.  The primary data will be released to EDRN specified sites upon approval by the two EDRN collaborating sites.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>LC-MS/MS via QqQ hybrid TRAP</_3:analyticMethod>
    <_3:abbreviatedName>Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds</_3:abbreviatedName>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>1) Secreted prostate specific markers.
2) Glycans specific to PCa versus benign.</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/&#13;&#10;"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:startDate>Jan  2 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>No</_3:blinding>
    <_3:aims>Aim 1.  Application of MRM to Quantitation of Urine Secretome Protein Biomarkers</_3:aims>
    <_3:aims>Aim 1.  Application of MRM to Quantitation of Urine Secretome Protein Biomarkers

Aim 2.  Application of MRM to Quantitation of EPS Protein Biomarkers

Aim 3.  Application of MRM to Glycoprotein Biomarker Analysis
</_3:aims>
    <_3:outcome>
</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/407"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds</_4:title>
    <_3:objective>A.&amp;nbsp;&amp;nbsp;&amp;nbsp;RATIONALE
The recent introduction of multiple reaction monitoring capabilities offers unprecedented capability to the research arsenal available to protein based biomarker discovery.  Specific to the discovery process this technology offers an ability to monitor specific protein changes in concentration and/or post-translational modification.  The ability to accurately confirm specific biomarkers in a sensitive and reproducible manner is critical to the confirmation and pre-validation process.  We are proposing two collaborative studies that promise to develop Multiple Reaction Monitoring (MRM) work flows for the biomarker scientific community and specifically for EDRN. 

B.&amp;nbsp;&amp;nbsp;&amp;nbsp;GOALS
The overall goal for this proposal is the identification of protein biomarkers that can be associated with prostate cancer detection.  The underlying goal is the application of a novel technological approach aided by MRM toward biomarker discovery.  An additional goal will be the dissemination of knowledge gained from these studies EDRN wide.
</_3:objective>
    <_3:objective>A.&amp;nbsp;&amp;nbsp;&amp;nbsp;RATIONALE</_3:objective>
    <_3:comments>
</_3:comments>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/101">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer</_3:abbreviatedName>
    <_4:title>Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/129">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/193"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>4D-ELF for CRC detection</_3:abbreviatedName>
    <_4:title>Spectral Markers for Early Detection of Colon Neoplasia</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/193"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/319">
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/134"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>383 HCC Cases/388 Cirrhosis Controls</_3:finalSampleSize>
    <_3:dataSharingPlan>According to EDRN guidelines data will be shared through public portal.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly.  The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage.  The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve &amp;#062; 90% sensitivity and &amp;#062; 85% specificity for the distinction of cirrhosis from HCC.  </_3:analyticMethod>
    <_3:abbreviatedName>Liver Reference Set (Full): Block (2010)</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Oct  1 2010 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>Sample Eligibility defined in DCP Protocol</_3:eligibilityCriteria>
    <_3:startDate>Aug  1 2010 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>We have developed a targeted glycoproteomic methodology that allows for the identification of glycoprotein biomarkers in serum. This simple methodology first identifies changes in N-linked glycosylation that occur with the disease. This change acts as a ?tag? so that we can extract out those specific proteins that contain that glycan structure. Our initial work in an animal model led to the discovery of a protein, GP73, which is 3 times more sensitive at detecting HCC than the current marker, AFP. In the animal model of HCC, the change in glycosylation was an increase in core fucosylation(Block et al. 2005). This change was also observed in people who developed HCC(Comunale 2006)</_4:description>
    <_3:blinding>All samples were blinded as part of the DCP protocol and then blinded during the sub-aliquot process at NCI-Frederick.</_3:blinding>
    <_3:aims>Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Liver Reference Set Application (Full): Block - Drexel Univ (2010)</_4:title>
    <_3:objective>The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis.  The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:objective>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/111">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:abbreviatedName>DCP</_3:abbreviatedName>
    <_3:finishDate>Feb 28 2008 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The primary goal is to compare the sensitivity and specificity of DCP to AFP for early stage HCC. We will test the null hypothesis that the ratio, TPF(DCP)/TPF(AFP) is larger than one, and similarly the null hypothesis FPF(DCP)/FPF(AFP) is less than one (Aim 2). 95% confidence interval for these two ratios, as well as that for differences between the two markers in TPF and FPF will be calculated. If both null hypotheses are rejected, we will conclude that DCP is superior to AFP in both TPF and FPF. If one null hypothesis is rejected (most likely for TPF) and another is inconclusive, the conclusion is that DCP is superior to AFP in TPF but inconclusive in FPF. A subsequent study will be required with a larger number of non-HCC cirrhosis patients to estimate the magnitude and direction of the difference in FPF. If neither null hypothesis is rejected, we will conclude that DCP is not superior to AFP in TPF or FPF. In that case, it is still of interest to see if the combination of two will improve the performance of either test. A joint confidence region of (TPF, FPF) for DCP (Aim 1), as well as that for AFP will be constructed. This will provide the performance measure of each biomarker for early stage HCC. To examine whether the performance of DCP depends on demographic or etiology of underlying liver disease (Aim 3), we will use logistic regression model. Taking ethnicity as an example, the logistic regression will have disease status as the dependent variable and independent variables will include the value of DCP, ethnicity indicator, and DCP by ethnicity interaction. The effect of clinical variables, e.g., etiology (no Hepatitis, HCV, HBV), and their interaction with DCP in predicting disease status will be examined in similar way. Of particular interest is to compare Hepatitis C-related HCC versus Hepatitis C-related controls and Hepatitis C negative HCC versus Hepatitis C negative controls due to the fact that Hepatitis C is the most common cause of cirrhosis and HCC in the USA.  To examine whether the combination of DCP and AFP will perform better than either test alone, we will use logistic regression with DCP or AFP alone, or a model with DCP, AFP, and their interaction term in the model, and compare their performance. If the combination does improve the classification, we will look at the linear combination of regression coefficients to find out the optimal combination as a classification rule. AFP-L3 was added to this study as an ancillary study. The data analysis of AFP-L3, as compared to AFP, is similar to that for DCP described above. We will also use a logistic regression entering DCP, AFP, and AFP-L3 into the model in different order to assess each marker?s independent additional contribution to ROC curve in addition to other marker(s). </_3:analyticMethod>
    <_3:estimatedFinishDate>Feb 14 2007 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:bmName>des-gamma carboxyprothrombin (DCP), alpha-fetoprotein (AFP)and AFP-L3</_3:bmName>
    <_3:dataSharingPlan>Upon publication data will be shared outside of EDRN.  Upon accrual completion and statistical analysis data will be shared within EDRN</_3:dataSharingPlan>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:startDate>Feb 14 2005 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>The DMCC provides each site with de-identified specimen labels for all serum, plasma and DNA aliquots.  Case/Control status can not be determined by any analysis lab.</_3:blinding>
    <_3:aims>The aims of this proposal are: (a) to determine the sensitivity and specificity of DCP for the detection of early HCC, (b) to compare the accuracy of DCP and AFP for the detection of early HCC, and (c) to determine whether demographic or etiology of underlying liver disease alter the expression of DCP or AFP. In order to achieve the aims of the study, we will enroll patients at 7 liver centers to perform a case control study of those with cirrhosis and those with early HCC. We will obtain the demographics, medical history, history of liver disease, social history (attention to lifetime smoking and alcohol), etiology of liver disease, family history, and clinical and laboratory data of patients with cirrhosis and early HCC. In addition, we will obtain serum, plasma and DNA for the evaluation of markers for HCC. All the data obtained will be maintained in a web-based database. We plan to enroll 450 HCC patients and 450 cirrhosis controls in order to target 190 early-stage HCC cases to achieve 90% power.  If 260 late-stage HCC cases are recruited before the target 190 early-stage HCC cases, then additional enrollment of late-stage HCC cases will be stopped. This is an important validation study of DCP, which may lead to the development of a clinically needed marker for HCC.</_3:aims>
    <_3:outcome>Not yet published</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/147"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/198"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/148"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/144"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/197"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/275"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/276"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/196"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/145"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/146"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/134"/>
    <_4:title>Validation of Serum Markers for the Early Detection of Hepatocellular Carcinoma</_4:title>
    <_3:objective>Using the guidelines for cancer biomarker validation suggested by Pepe et al. (23), we propose to perform a Phase 2 study of DCP for the detection of early stage HCC.  In this proposal, we plan to perform a larger case-control study to compare the sensitivity and specificity of DCP and AFP alone and in combination in differentiating patients with all stages of HCC and more importantly those with early HCC from patients with cirrhosis. We plan to enroll consecutive patients with HCC seen at 7 centers in the United States. Controls are frequency matched to cases (all center combined) using the following criteria:  age (10 years), gender (+10%) and etiology of liver disease (viral vs non-viral (+5%). Within each participating institution, there will be an equal number (+20%) of cases and controls.</_3:objective>
    <_3:finalSampleSize>422 HCC Cases (208 Early Stage and 214 Late Stage). 419 Cirrhosis Controls.  5 Cirrhosis Controls who progressed to HCC.</_3:finalSampleSize>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>450 HCC Liver Cancer Cases, 450 Cirrhosis Controls</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/73">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Detecting Breast Cancer Signatures in Body Fluids</_3:abbreviatedName>
    <_4:title>Detecting Breast Cancer Signatures in Body Fluids</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/242">
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>300 breast cancer Stage I/II patients with no recurrence; 200 breast cancer Stage I/II patients with recurrence; 200 late stage breast cancer patients; 200 patients with non-malignant breast disease; 200 patients with autoimmune disease; 400 healthy control serum donors with no history of cancer; 300 other cancers, 30 each from 10 different tumor sites.</_3:finalSampleSize>
    <_3:dataSharingPlan>As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.</_3:analyticMethod>
    <_3:estimatedFinishDate>Jul 31 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:abbreviatedName>Early Detection of Breast Cancer Using Autoantibody Markers</_3:abbreviatedName>
    <_3:bmName>Autoantibodies</_3:bmName>
    <_3:startDate>Aug  2 2005 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>N/A</_3:blinding>
    <_3:aims>The aims are organized in 4 subgroups: Aims 1-4 will identify the more informative antigen biomarkers for use on our microarrays. Aim 5 will identify the protein sequences in these informative cDNA clones. Aims 6-8 will provide validation on larger serum sample sets. Aims 9-10 will establish a format of the diagnostic suitable for collaboration with other EDRN components.
Aim 1. Employ high throughput antigen cloning and identification of a suitable number of biomarkers to accurately identify invasive breast cancer.
Aim 2. Use machine-learning techniques such as classification trees and neural networks to develop classifiers able to distinguish women with breast cancer from healthy subjects.
Aim 3. Estimate the test characteristics (sensitivity, specificity, accuracy) of the antigen markers for distinguishing sera of breast cancer patients from control sera.
Aim 4. Eliminate those antigen markers that cross-react with patients with nonmalignant breast diseases and autoimmune diseases.
Aim 5. Determine the DNA sequence of the cDNA clones of validated markers.
Aim 6. Validate the markers on larger sample sets. We will use antigen clones to detect serum antibodies in the BCPS serum set. We will perform a secondary analysis of the reaction of antibodies in the patients? sera to identify whether there are antigen reactions indicative of a high likelihood of recurrence.
Aim 7. Determine the accuracy of the test in sera prospectively derived from women who later developed breast cancer.
Aim 8. Eliminate antigen clones that react with sera from people with other cancers.
Aim 9. Prepare of purified antigen-containing proteins for the penultimate antigen diagnostic array.
Aim 10. Perform internal and external validation tests with EDRN partners.
</_3:aims>
    <_3:outcome>To date, we have devised an approach to cloning biomarkers that focuses on the goal of identifying breast cancer at Stage I. We have applied this approach to early stage breast cancer and have some preliminary data to indicate the technology is feasible. The goal of this application is to apply this technology to develop: 1) an early detection assay for breast cancer in asymptomatic women and           2) a novel prognostic approach for women with early stage breast cancer, a disease from which 25-30% of women will relapse in 5 years post diagnosis.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/238"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Early Detection of Breast Cancer Using Autoantibody Markers</_4:title>
    <_3:objective>To identify large numbers of antigens that can be used to recognize the presence of cancer by detecting antibodies to tumor proteins in the serum of the test subjects.  Our technology will provide an early detection test for breast cancer in asymptomatic women. We will use bioinformatics techniques to analyze these protein microarray-immunoassays to discriminate between cancer patients and healthy subjects so as to detect disease prior to standard diagnoses as well as discriminate patients with benign conditions or other cancers that might be a false positive in less specific assays.</_3:objective>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>30 breast cancer Stage I patients with recurrence
30 breast cancer Stage I patients with no recurrence
120 healthy control serum donors with no history of cancer</_3:plannedSampleSize>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/126">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>100 cases and 100 controls</_3:finalSampleSize>
    <_3:dataSharingPlan>Data used in a publication will be made publicly available upon publication to allow other investigators access to the data.

</_3:dataSharingPlan>
    <_3:finishDate>Jan 17 2008 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The primary analysis for this study is to identify proteins/peptides that have potential as colon cancer early detection or risk prediction markers for subsequent validation. The secondary aim is to see if some proteins/peptides are complementary in their early detection abilities so their combinations will improve their sensitivity and specificity. Since thousands of protein/peptides will be identified and/or quantified, one important issue is to quantify and control the False Discovery Rate (# of false positive finding / # of selected markers as differentially expressed) and maintain reasonable power to detect truly differentially expressed markers. Another important feature of the data analysis is that the derived data from mass spectrometry critically depends on the algorithms of identifying the peptides, assigning protein identities and intensities. Coordinating center biostatisticians need work closely with proteomics bioinformaticians and computational biologists with expected iterations between data processing and data analyses.</_3:analyticMethod>
    <_3:abbreviatedName>EDRN/WHI COLON</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Jan 17 2007 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>proteins, peptides, </_3:bmName>
    <_3:startDate>Jan 17 2006 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>The investigators will be blinded to disease status. For laboratories that use two-color system, the disease status group label will be A and B. After the raw data has been generated and sent to DMCC (or CPAS), the sites will be un-blinded to facilitate their investigations using disease status information.
 A set of split duplicate specimens from 10 additional controls will be sent to each lab. These specimens will be integrated, as if 10 additional matched pairs, with the 100 matched case-control pairs, in a blinded fashion.
</_3:blinding>
    <_3:aims>Specific Aims are identified by each assay laboratory.</_3:aims>
    <_3:outcome>Project continuing</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/250"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/289"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/290"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/249"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/281"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>EDRN-WHI Pre-Clinical Colon Ca Specimens</_4:title>
    <_3:objective>Specifically, it is proposed to assess plasma proteins from postmenopausal women diagnosed with colon cancer within a span of 18 months after year-3 OS blood draw and from appropriate matched controls enrolled in the WHI OS study. The range of case-control differences sought in plasma include:

1   Detection and identification of proteins that may be derived from tumor cells through the classical secreted protein pathway and through non-classical pathways (eg protein cleavage and release) or through cell turnover.
2   Detection and identification of protein changes associated with the host response that occur during tumor development and that may be related to inflammation, angiogenesis, infiltration of tumor with host cells and other processes.
3   Identification of tumor derived proteins that induce a humoral immune response in the form of autoantibodies that are detectable at the preclinical stage.
</_3:objective>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>100 colon cancer cases from WHI and an equal number of pair matched controls from the Observational Study (OS)</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Glycomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/291">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/522"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/522"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/118"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>BRSCW Applicant: Wilson (2007)</_3:abbreviatedName>
    <_3:startDate>Oct 10 2007 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Oct  9 2008 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>BRSCW Applicant: Wilson - EIC Laboratories, Inc (2007)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/24">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/84"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>NYU Lung Cancer Biomarker Center</_3:abbreviatedName>
    <_4:title>NYU Lung Cancer Biomarker Center</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:blinding>n/a</_3:blinding>
    <_3:aims>A. SPECIFIC AIMS
   1. To develop and prospectively follow a large cohort at high-risk for lung cancer.   Individuals are recruited to one of two different study groups: The Screening Cohort includes people with and without increased risk for lung cancer. The Rule-Out Lung Cancer Patient Group is recruited from patients referred for evaluation of suspicious nodules.  All individuals answer a questionnaire, obtain PFTs, chest CT scan, sputum induction and phlebotomy.  For patients undergoing lung resections or biopsies, tissue samples are collected and banked.  Individuals are recruited for research bronchoscopy.  All participants are then followed prospectively.   The specimens obtained are banked and used for biomarker discovery and validation studies. 
   2. To identify and validate biomarkers for the early detection of lung cancer, and to describe preneoplastic cellular changes and lesions. Biomarker studies include DNA adducts, DNA methylation, protein markers, and other collaborations.  Preneoplasia studies include: fluorescence and Superdimension bronchoscopies to obtain biopsies of preneoplastic lesions and biomarker studies in individuals with preneoplasias.  
</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/84"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/71">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Breast tissue array</_3:abbreviatedName>
    <_4:title>Breast tissue array</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/120">
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/510"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:dataSharingPlan>Application for specimen use in place.  Authorized labs will release their results to the DMCC.  Upon publication, data will be shared.</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>To collect biologic samples on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of risk and prognosis of prostate cancer</_3:objective>
    <_3:startDate>Jul  1 2006 12:00AM</_3:startDate>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:estimatedFinishDate>Feb 28 2007 12:00AM</_3:estimatedFinishDate>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>PROS-REF</_3:abbreviatedName>
    <_3:blinding>All samples will be sent to NCI-Frederick for blinding and set assembly.</_3:blinding>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Standard Specimen Reference Set:  Prostate</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>165 Prostate Cancer Cases
210 Bx Benign Controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/82">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:finishDate>Jun  1 2004 12:00AM</_3:finishDate>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1256"/>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>MLDA in pancreatic cancer</_3:abbreviatedName>
    <_4:title>Mutational load distribution analysis (MLDA) in pancreatic cancer</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:finalSampleSize>17 pancreatic juice samples</_3:finalSampleSize>
    <_3:cancerType>157                                                                                                 </_3:cancerType>
    <_3:outcome>Certain p16 mutation carriers showed mutation elevations in the specific Ki-ras and p53 alleles significantly higher than normal, similar to controls with pancreatitis.  Two individuals from separate families started out with &amp;quot;low risk&amp;quot; readings subsequently converted to &amp;quot;high risk&amp;quot; categorization and remained there in each sequential exam.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/69"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:bmName>Ki-ras</_3:bmName>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/316">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/147"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/148"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/144"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/275"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/145"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/146"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>DCP2</_3:abbreviatedName>
    <_3:startDate>Apr  1 2010 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Mar 31 2015 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Early Detection and Prognosis of Hepatocellular Carcinoma</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>3</_3:phasedStatus>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/290">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText> </_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>MALDI Dilution Data</_3:abbreviatedName>
    <_4:title>MALDI Dilution Data: Randolph</_4:title>
    <_3:protocolType>Other specify</_3:protocolType>
    <_3:cancerType>                                                                                                    </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/91">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas</_3:abbreviatedName>
    <_4:title>SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/116">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/73"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/128"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/411"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/202"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/84"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_4:title>EDRN Resource Network Exchange</_4:title>
    <_3:abbreviatedName>ERNE</_3:abbreviatedName>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/315">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/589"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/589"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/120"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Prostate Ref Set: Isaacs 2010</_3:abbreviatedName>
    <_3:startDate>May 21 2010 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:plannedSampleSize>50 Cases/50 Controls using Citrate Cellular Component from the Prostate Reference Set</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/87">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Establishment of a serum standard for use in high-throughput proteomic</_3:abbreviatedName>
    <_4:title>Establishment of a serum standard for use in high-throughput proteomic</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174, 185                                                                                            </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/63"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/238">
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:finishDate>Dec 31 2008 12:00AM</_3:finishDate>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:objective>To evaluate the effects of receptor status on circulating biomarker levels.</_3:objective>
    <_3:startDate>Jan  1 2007 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:bmName>amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1&amp;#61537; and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor &amp;#61537;, tissue necrosis factor &amp;#61537;, urokinase plasminogen activator, vascular endothelial growth factor</_3:bmName>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:aims>To analyze plasma levels of 24 proteins in 60 samples from women with either benign breast disease, or Her+ or ER+ cancers.</_3:aims>
    <_4:title>Year 2 Collaborative Project - UCSF and Battelle PNWD</_4:title>
    <_3:analyticMethod>ELISA microarray</_3:analyticMethod>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:abbreviatedName>Year 2 Collaborative Project - UCSF and Battelle PNWD</_3:abbreviatedName>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/274">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Upon publication analysis will be shared</_3:dataSharingPlan>
    <_3:blinding>All samples are blinded by the DMCC</_3:blinding>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/510"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>PCA3 testing of processed urine specimens will take place at John Hopkins University (Dr Sokoll) and Gen-Probe (Dr. Groskopf) (see Appendix 5). Testing will be performed and analyzed according to the method described by Groskopf(8). The Hopkins EDRN Biomarker Reference Laboratory will assay 100% of the samples and the Gen-Probe laboratory will assay 10% as quality control.  

Processed urine specimens will be tested in duplicate at both laboratories with the PCA3 Assay on the Gen-Probe Systems. The calibration curve will be tested in triplicate and the controls will be tested in duplicate. The mRNA results for PCA3 and PSA for each subject must be generated from the same processed urine specimen tube.
</_3:analyticMethod>
    <_3:abbreviatedName>PCA3</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Jan 15 2012 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>PCA3</_3:bmName>
    <_3:eligibilityCriteria>Inclusion
&amp;#149;Males greater than or equal to age 18
&amp;#149;Patient scheduled for prostate biopsy for any of the following reasons:
oPSA &amp;#062;2.0 ng/ml
oElevated PSA velocity (&amp;#062;0.4 ng/ml/yr)
oLower PSA value with other risk factors for PCa (e.g.; family history)
oPrior ASAP or HGPIN
oAbnormal DRE
o% free PSA &amp;#060;15%
&amp;#149;Finasteride/dutasteride and other medications for BPH and ED are allowable but will be recorded 
Exclusion
&amp;#149;History of PCa
&amp;#149;Urine not collected post DRE prior to index prostate biopsy
oBlood can be collected up to 1 month before urine
oUrine can be collected up to 1 month before index biopsy
&amp;#149;Index prostate biopsy with &amp;#060;10 cores and without extended template
&amp;#149;Index prostate biopsy pathology report unavailable
&amp;#149;Participating in an intervention trial for prostate disease
&amp;#149;Prior surgical (open or endoscopic) or minimally invasive treatment (TUNA/TUMT) for BPH
&amp;#149;Prior saturation biopsy defined as at least 30 cores
&amp;#149;Prior prostate biopsy within 6 months
&amp;#149;Prior PCA3 test performed for clinical purpose
&amp;#149;Consented more than 3 months before index biopsy
</_3:eligibilityCriteria>
    <_3:startDate>Jan 16 2009 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_4:description>The Early Detection Research Network (EDRN) is a National Cancer Institute (NCI) funded multi-center collaborative research group. Resources include a biomarker development laboratory at the University of Michigan, biomarker reference laboratories and clinical epidemiological validation centers at the University of Michigan, Beth Israel Deaconess-Harvard University, University of Texas at San Antonio and Johns Hopkins University (see Appendix 6 for list of participating sites). Objectives of the EDRN include development and independent validation of promising biomarkers and technologies for early cancer detection and collaboration amongst academic and industrial leaders in molecular biology, molecular genetics, clinical oncology, computer science, public health and clinical application for early cancer detection. This study will fully utilize the EDRN infrastructure to validate a promising new urinary biomarker for prostate cancer, PCA3 and to create a novel urinary reference set for future validations.

Total number of 850 men will be recruited into the study
</_4:description>
    <_3:aims>Primary Specific Aims

Aim 1:To evaluate the PPV of PCA3 for initial biopsy population and NPV of PCA3 for repeat biopsy population in a multi-center prostate biopsy cohort of men without prior history of prostate cancer

Aim 2:To develop a novel urinary reference set consisting of whole urine /urine sediment as well as plasma/serum necessary for future pre-validation studies of urinary biomarkers.

Secondary Aims

Aim 1:To evaluate the sensitivity, specificity, PPV, NPV, and absolute risk prediction by PCA3 alone and multiplexed with other biomarkers and clinical variables in the detection of prostate cancer overall, and in the detection of high grade cancer

Aim 2:To evaluate the correlation between PCA3 and prostate biopsy tumor grade

</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/528"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/125"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/546"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/491"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/529"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/527"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/525"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/510"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/142"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/526"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>PCA3 Validation Study and Urinary Reference Set</_4:title>
    <_3:objective>Independent of serum PSA level, PCA3 score will refine the risk of having cancer detected on an extended template prostate biopsy.</_3:objective>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/75">
    <_3:design>Convenience</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_4:title>Research Depository of Normal and Neoplastic Human Tissues</_4:title>
    <_3:abbreviatedName>Research Depository of Normal and Neoplastic Human Tissues</_3:abbreviatedName>
    <_3:protocolType>Single</_3:protocolType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/61">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Registry</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Protocol for Comparing Promoter Hypermethylation Methods in NSCLC</_3:abbreviatedName>
    <_4:title>Protocol for Comparing Promoter Hypermethylation Methods in NSCLC</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/72">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Registry</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Biomarker Dev Lab At Moffitt Supplement</_3:abbreviatedName>
    <_4:title>Biomarker Dev Lab At Moffitt Supplement</_4:title>
    <_3:protocolType>Other specify</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/117">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Polyp Prediction Study</_3:abbreviatedName>
    <_4:title>Polyp Prediction Study</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153, 154                                                                                            </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/64">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/73"/>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/73"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>New Biomarkers &amp; Dysplastic Respiratory Epithelium</_3:abbreviatedName>
    <_4:title>New Biomarkers &amp; Dysplastic Respiratory Epithelium</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/73"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/67">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>750</_3:finalSampleSize>
    <_3:dataSharingPlan>All data is housed with the DMCC.  Pending approval by the PI (Semmes) and DMCC (Ziding) the data is made available to requestors as raw or processed format.</_3:dataSharingPlan>
    <_3:finishDate>Jan  1 2007 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>SELDI-TOF, MALDI-TOF/TOF, SELDI-QStar</_3:analyticMethod>
    <_3:objective>Collection of bodu fluids for the purpose of early validation of the SELDI-TOF based assay for detection of PCa.  The fluids were also utilized for determining analytical reproducibility for several MS platforms.</_3:objective>
    <_3:bmName>m/z pattern</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/540"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1055"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1053"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/548"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/708"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/539"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/524"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1056"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/525"/>
    <_4:description>Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent diagnostic tool. At the center of these efforts is the application of SELDI-TOF-MS and artificial intelligence algorithms by the EDRN BDL site at Eastern
Virginia Medical School and the DMCC respectively. When the expression profiling process was applied to sera from individuals with prostate cancer (N=197), BPH (N=92) or from otherwise healthy donors (N=97) we achieved an overall misclassification rate of &amp;#060;10%. The sensitivity was 83% and the specificity was 100%
with an overall positive predictive value of 91.15%. This result is a significant improvement over PSA which presents as only 25% specificity and &amp;#062;90% sensitivity. Since this represents a noticeable improvement in current clinical approach we are proposing to embark upon a validation process. The described studies are
designed to address validation issues and include three phases. Phase 1; Synchronization of SELDI Output within the EDRN-Prostate-SELDI Investigational Collaboration (EPSIC); addressing portability (A) Synchronize SELDI instrumentation and robotic sample processing across the EPSIC using pooled serum(QC); (B) Establish the portability and reproducibility of the SELDI protein profiling approach within the EPSIC using normal and prostate cancer patient?s serum from a single site; (C) Establish robustness of the
approach toward geographic, sample collection and processing differences within EPSIC using case and
control serum from five different sites. Phase 2; Population Validation Establish geographic variability and robustness in a large cross-sectional study among different sample population. Phase 3; Clinical Validation;
validate the serum protein expression profiling coupled with a learning algorithm as a means for early detection of prostate cancer using longitudinal PCPT samples. We have assembled a cohesive multi-institutional team for completing these studies in a timely and efficient manner. The team consists of five EDRN laboratories,
DMCC and CBI and the proposed budget reflects the total involvement.</_4:description>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>There is a blinding protocol in place.</_3:blinding>
    <_3:aims>The specific aims are elaborated in the Validation protocol submitted earlier.</_3:aims>
    <_3:outcome>Highly reproducible technique.
Unable to detect PCa in the new cohort.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>Body Fluids as a Source of Diagnostic Biomarkers: Prostate</_4:title>
    <_3:abbreviatedName>Body Fluids as a Source of Diagnostic Biomarkers: Prostate</_3:abbreviatedName>
    <_3:comments>The three article that emerged from this study have been well referenced and represent the new standard for validation of high-throughput proteomics data.  The last two mansucripts were published back to back in Clinical Chemistry with three invited editorials to comment on the research.</_3:comments>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/77">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Molecular Genetics of Urinary Bladder Carcinoma</_3:abbreviatedName>
    <_4:title>Molecular Genetics of Urinary Bladder Carcinoma</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/84">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum</_3:abbreviatedName>
    <_4:title>HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/86">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Early Molecular Detection of Invasive Bladder Cancer by Urine Examination</_3:abbreviatedName>
    <_4:title>Early Molecular Detection of Invasive Bladder Cancer by Urine Examination</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/118">
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:abbreviatedName>BRSCW</_3:abbreviatedName>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:analyticMethod>N/A</_3:analyticMethod>
    <_3:estimatedFinishDate>Sep  1 2006 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:bmName>N/A</_3:bmName>
    <_3:startDate>Jun 22 2005 12:00AM</_3:startDate>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:blinding>The pooled case specimens and replicate control specimens cannot be associated with any individual subject. The identity of the control subjects has been retained by the commercial blood bank and is unknown to Partner?s Investigators. Thus, the ability to link the specimen to a specific individual is impossible for the investigator receiving the specimen.</_3:blinding>
    <_3:aims>50 pre- and 50 post-menopausal healthy women who have no personal nor any strong family history of cancer will be recruited through the Research Blood Components and have between 225 -250 ml of blood drawn yielding sufficient sera for 350 0.3mL aliquots on each individual subject plus sufficient residual sera which will be pooled to construct 350 sets of 8 replicate serum specimens. At the same time, pooled sets of ovarian cancer cases stratified by menopausal status and histologic type will also be created providing 4 sets of 250 0.3ml aliquots from case recruited through an existing IRB protocol (Preoperative Predictors of Findings at Pelvic Surgery #2000p001678).  Ca-125, CEA, and Ca 15-3 will be measured as standard markers in all subjects including the individual cases and controls as well as in the set of pooled specimens.  The reference sets will be assembled and stored in barcoded capillary tubes in liquid nitrogen.  Investigators requesting specimens to evaluate a new marker would receive a ?blinded? test control panel of 200 individual controls, 8(replicate) pooled control specimens (to yield a co-efficient of variation on the assay), and a set of 4 pooled case specimens.  Investigator would report the results of their assay to the EDRN data coordinating center which would  provide statistical output including the means and standard errors for the marker in all controls and the pre-and post-menopausal groups, the coefficient of variation for the marker, estimates of the marker in the pooled specimens in relation to the control distribution, and performance relative to standard markers.  Markers, whose levels in the case pools are more extreme than the best standard marker relative to the distribution in controls, would be promising candidates to move to the next level of validation.  </_3:aims>
    <_3:outcome>N/A</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/305"/>
    <_4:title>Biomarker Reference Sets for Cancers in Women</_4:title>
    <_3:objective>The purpose of this study is to develop a standard reference set of specimens for use by investigators participating in the National Cancer Institutes Early Detection Research Network (EDRN) in defining false positive rates for new cancer biomarkers in women. </_3:objective>
    <_3:cancerType>174, 182, 183                                                                                       </_3:cancerType>
    <_3:plannedSampleSize>95 healthy women with no personal or strong family history of cancer and 20 identical replicates to measure assay variation.  275 serum aliquots of 0.3ml for all controls and an additional serum pool for creating the replicates.</_3:plannedSampleSize>
    <_3:fieldOfResearch>Metabolomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
    <_3:fieldOfResearch>Hypermethylation</_3:fieldOfResearch>
    <_3:fieldOfResearch>Glycomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Epigenomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/230">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Pre-Validation of Metabolomic Biomarkers of Prostate Cancer</_3:abbreviatedName>
    <_3:startDate>Aug  1 2007 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_4:title>Pre-Validation of Metabolomic Biomarkers of Prostate Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>n/a</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/107">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett?s Esophagus Progression to Dysp</_3:abbreviatedName>
    <_4:title>GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett?s Esophagus Progression to Dysplasia and Adenocarcinoma</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>150                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/69"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/114">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>N=100 (tumor samples, urine samples)</_3:finalSampleSize>
    <_3:dataSharingPlan>All data are available for query and download from our public database, UESC.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples. </_3:analyticMethod>
    <_3:abbreviatedName>Prostate &amp; Bladder Cancer Biomarkers</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <_3:estimatedFinishDate>May 18 2009 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>CD90, AGR2, CEACAM5</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/518"/>
    <_4:description>CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.</_4:description>
    <_3:startDate>May 19 2004 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:blinding>n/a</_3:blinding>
    <_3:aims>Sort cancer cells from tumor specimens

Determine gene expression (transcriptome) by Affymetrix DNA arrays

Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins

Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression</_3:aims>
    <_3:outcome>CD90, AGR2, CEACAM5 are all up-regulated in prostate cancer</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/192"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Biomarkers for Prostate and Bladder Cancer</_4:title>
    <_3:objective>To identify potential cancer-specific protein biomarkers via genomic analysis of differential gene expression between cancer cells and their normal counterpart. 
To use proteomic analysis for quantitative detection of these proteins in urine.</_3:objective>
    <_3:comments>Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.  </_3:comments>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>No specific sample size listed in protocol.  Researcher will utilize prostate tumor tissue, prostate normal tissue, bladder tumor tissue, bladder normal tissue, and urine.</_3:plannedSampleSize>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/89">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Detecting breast cancer protein signatures in body fluid</_3:abbreviatedName>
    <_4:title>Detecting breast cancer protein signatures in body fluid</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/79"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/195">
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/491"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/545"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/441"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/428"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/510"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/420"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/429"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/426"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/142"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/424"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/442"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:dataSharingPlan>All recruiting sites will enter their data into the Validation Studies Information Management System (VSIMS), a secure database maintained by the Early Detection Network (EDRN) Data Management Coordinating Center (DMCC).</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/142"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:objective>Primary Objective:
To discover and confirm biomarkers that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.

Secondary Objectives:
To determine the proportion of patients on active surveillance who progress based on the above criteria.
To determine the clinical predictors of disease progression.
To measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. 
</_3:objective>
    <_3:startDate>Dec 19 2007 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:estimatedFinishDate>Dec 19 2010 12:00AM</_3:estimatedFinishDate>
    <_3:analyticMethod>The primary objective of this repository is to discover and validate biomarkers predicting aggressive disease, with emphasis on validation. The sample size and power is based on validation of a biomarker after its initial discovery. Since this cohort of men has already elected AS, a desirable biomarker should have high specificity so that clinicians will minimize the proportion of those men advised for more aggressive treatment, while still identifying the subset of men with high risk for progression. Therefore, we evaluate the sensitivity of a biomarker predicting aggressive disease at 95% specificity. We assume the threshold for 95% specificity needs to be estimated from this study, i.e., there is no pre-fixed threshold. This is more realistic because estimating the threshold usually requires a large study. The proportion of disease progression at 3 and 5 years from diagnosis is estimated at 25% and 33%. We want 90% power to confirm a sensitivity better than 10% (unacceptable) if the true sensitivity is 30% or better, at 95% specificity. Point estimate of sensitivity, specificity, and threshold and their 95% confidence intervals will be calculated. The sample size also depends on the slope of Receiver Operating Characteristic (ROC) curve at 95% specificity, usually quite steep when specificity is near 100%. We used 4 as the slope parameter for power analysis.

Based on above assumptions, for a cohort with at least 3 years follow up, this study requires 100 men with disease progression and 300 men without progression, totally n=400. For a cohort with at least 5 years follow up, this study requires 125 men with progression and 250 men without progression, total n=375. Therefore, the total needed person-years follow up should be 375*5=1,875.

The estimated number of patients elected for AS is about 350 in five sites combined. Given a conventional 25% recruitment rate, we expect 100 patients per year accrual. With 25% loss of follow-up, we estimate that each year?s 100 recruited men will finally contribute 375 person-years by the end of 5 years. It should be noted that we need full 5 years follow up to ensure that the men who had not progressed are indeed non-progressors, not false negatives. By the same reason, men after 5-years follow up will contribute little to the total person-years follow up because their risk of progression is felt to be low. Therefore, the study needs continuing 5 years recruitment and subsequent 5-years follow up with minimum 100 recruitment per year and a minimum 75% follow up rate.</_3:analyticMethod>
    <_3:abbreviatedName>PASS</_3:abbreviatedName>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Prostate Active Surveillance Study</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>125 men with prostate cancer progression and 250 men without prostate cancer progression, over 5 years of follow-up.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/236">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>500 HNSCC patients (250 early and 250 late stage) and 500 control non-cancer patients</_3:finalSampleSize>
    <_3:dataSharingPlan>As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.</_3:analyticMethod>
    <_3:abbreviatedName>Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <_3:estimatedFinishDate>Feb 28 2009 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>Autoantibodies</_3:bmName>
    <_3:startDate>Mar  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>N/A</_3:blinding>
    <_3:aims>Aim 1:  Assess the sensitivity of the current diagnostic assay using some additional informative biomarkers added to the current diagnostic panel.  
Aim 2:  Confirm the validity of this diagnostic strategy for early HNSCC detection based on pattern of serum immunoreactivity against a biomarker panel in collaboration with 2 other EDRN sites.
</_3:aims>
    <_3:outcome>We have previously demonstrated the feasibility of head and neck cancer detection based on analysis of patterns of serum immunoreactivity against a panel of 130 cancer biomarkers.  The performance of this panel of 130 markers in discriminating cancer from noncancer serum samples was excellent with an accuracy of 84.9%, sensitivity of 79.8% and specificity of 90.1% and represented a significant improvement over current diagnostic accuracy in the primary care setting.  We are currently in the process of improving the accuracy of this current diagnostic panel by incorporating additional biomarkers identified by biopanning against those cancer sera which were most frequently misclassified.  
Diagnostic accuracy of this new diagnostic panel will then be assessed using serum samples from the other 2 EDRN sites.
</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/232"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer</_4:title>
    <_3:objective>Our long term goal is to improve survival of patients with head and neck squamous cell carcinoma (HNSCC) through early detection using simple noninvasive serum assays in an ELISA-like platform.  The objective of this proposal is to improve and confirm the validity of a diagnostic serum assay based on a panel of cancer-specific biomarkers for early cancer detection in patients with HNSCC.  Our central hypothesis is that the detection of antibody responses to HNSCC-specific antigens, using a panel of biomarkers, can provide sufficient sensitivity and specificity suitable for clinical testing in the primary setting to screen and diagnose HNSCC in high risk populations to improve early detection.</_3:objective>
    <_3:cancerType>144, 143, 148, 140, 160, 147, 146, 149, 145, 141                                                    </_3:cancerType>
    <_3:plannedSampleSize>Sera from 500 HNSCC patients (250 early and 250 late stage)
Sera from 500 control patients</_3:plannedSampleSize>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/93">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>SELDI Profiling of serum and urine (bladder cancer studies)</_3:abbreviatedName>
    <_4:title>SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/185">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:eligibilityCriteria>3.1 Cases (Pancreatic Cancer)
Patients will be consented prior to surgery.
A. No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
B. Must have undergone complete surgical resection of the tumor with curative intent including the
presence of negative margins and a pathologic staging of I or IIA.
C. Must have histological verification of a pancreatic adenocarcinoma
D. Must not have received preoperative chemoradiation (neoadjuvant) therapy due to our inability to
adequately stage these patients.
E. Able to give informed consent.
F. Blood sample must be obtained within the past 2 weeks prior to surgery/anesthesia according to
procedure described in Appendix D.
Post-Enrollment Criteria: Inclusion of the patient in the proposed validation set is dependent on the results
of the surgery. The patient must have undergone complete surgical resection of the tumor with curative
intent including the presence of negative margins and a pathologic staging of I or IIA. Samples from any
patients not meeting these criteria will be used in a discovery set.
3.2 Controls
Three different control groups are proposed for this reference set: chronic pancreatitis patients, acute
benign biliary obstruction patients and healthy controls. The cases and controls are required to have a
similar age distribution. Although we will attempt to keep the same number of cases and controls within
each site (1 to 3 ratio), age distribution does not have to be similar for cases and controls within each site.
An algorithm developed by Feng and colleagues will be used to recruit cases and controls across multicenters
to ensure that the cases and controls are frequency matched by age. Eligibility criteria for each of
Page 4 of 7
the controls groups are described below. Control specimens will not be collected until 10 post-operative
PC cases have been successfully enrolled in the study.</_3:eligibilityCriteria>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:dataSharingPlan>Recipients of the reference set will sign a data sharing agreement</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/156"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>The primary objective of the EDRN Pancreatic Cancer Working Group Proposal is to create a reference set
consisting of well-characterized serum/plasma specimens to use as a resource for the development of
biomarkers for the early detection of pancreatic adenocarcinoma. The testing of biomarkers on the same
sample set permits direct comparison among them; thereby, allowing the development of a biomarker panel
that can be evaluated in a future validation study. Additionally, the establishment of an infrastructure with
core data elements and standardized operating procedures for specimen collection, processing and storage,
will provide the necessary preparatory platform for larger validation studies when the appropriate
marker/panel for pancreatic adenocarcinoma has been identified.</_3:objective>
    <_3:startDate>Nov 26 2007 12:00AM</_3:startDate>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/341"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/156"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/417"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/418"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/416"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/419"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/412"/>
    <_3:cancerType>157                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>PANCREATIC-REF</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Standard Specimen Reference Set:  Pancreatic</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>60 Pancreatic Cases, 60 chronic pancreatitis controls, 60 biliary obstruction controls, 60 healthy controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/280">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Lab Data will be sent to DMCC, analyzed and shared according to LCBG/NCI guidelines.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Briefly, the nonparametric Kruskal-Wallis test will be used to examine the relationship between KLK levels, pathology, and clinical information. To evaluate the KLK for disease screening and diagnosis, the classification accuracy will be assessed using receiver operating characteristic (ROC) curves. The ROC curve will plot the true positive fraction (TPF) versus the false positive fraction (FPF) for the set of rules that classify a subject as ?test-positive? i.e., if the marker value exceeds a threshold value, where threshold varies over all possible values. It quantifies how well a marker discriminates between diseased and non-diseased individuals. We will perform the ROC analysis first on individual KLK and then in combination. We will use an algorithm that renders a single composite score using the linear predictor, fitted from a binary regression model. A stepwise regression procedure will be used to select markers in the panel with or without additional clinical variables.</_3:analyticMethod>
    <_3:abbreviatedName>Lung Cancer Specimen Reference Set A (Full) Application:  Goodglick/Diamandis (2009)</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Mar 25 2009 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>KLK8, 11, 12, 13, and 14 </_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>See Lung Reference Set A</_3:eligibilityCriteria>
    <_3:startDate>Mar 26 2009 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>Samples were blinded at NCI-Frederick</_3:blinding>
    <_3:aims>Aim 1. We will coordinate with the Lung Cancer Biomarker Committee to obtain aliquots of serum reference set A (i.e., Phase II validation set: 180 cases and 180 controls, 75 other cancer controls). The characteristics of these sample sets have been described on the EDRN website.
Aim 2. Two independent sites (UCLA and University of Toronto) will conduct ELISA tests on blinded serum samples for KLK8, 11, 12, 13, and 14. These assays have been well described previously, so we anticipate no technical hurdles. All samples will be run in duplicate. 
Aim 3. Data will be analyzed by the DMCC for both single KLK expression as well as for the entire panel (KLK8, 11, 12, 13, and 14) as previously described (1). 
</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/239"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Lung Cancer Specimen Reference Set A (Full) Application:  Goodglick/Diamandis (2009)</_4:title>
    <_3:objective>To study of the utility of KLK8, 11, 12, 13, and 14 profiles in diagnosing lung cancer.</_3:objective>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>180 cases, 180 high risk controls with lesions and 75 other cancer controls</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/92">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>SELDI biomarker discovery and serum protein profiling of lung cancers</_3:abbreviatedName>
    <_4:title>Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/196">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/190"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/161"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/190"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies</_3:abbreviatedName>
    <_3:startDate>Feb  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>157                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jul 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/190"/>
    <_4:title>Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/321">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/614"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/614"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/115"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Lung Reference Set A (Full) Applicant: Takacs - Biosystems (2010)</_3:abbreviatedName>
    <_3:startDate>Aug 24 2010 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Dec 24 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Lung Reference Set A (Full) Applicant: Takacs - Biosystems (2010)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:plannedSampleSize>Lung Reference Set A</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/289">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/332"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/332"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/118"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>BRSCW Applicant: Mathew (2006)</_3:abbreviatedName>
    <_3:startDate>Dec 21 2006 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Dec 20 2007 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>BRSCW Application: Mathew - Meso Scale (2006)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/70">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Expression based markers for breast cancer detection</_3:abbreviatedName>
    <_4:title>Expression based markers for breast cancer detection</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/194">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma</_3:abbreviatedName>
    <_3:startDate>Jan  2 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>189                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_4:title>Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>30 normal tissue samples, 30 tumor tissue samples from same patient</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/124">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/201"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Barrett&amp;#39;s -Associated Carcinogenesis</_3:abbreviatedName>
    <_4:title>Molecular Basis of Barrett&amp;#39;s -Associated Carcinogenesis</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>150                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/201"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/28">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Registry</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:objective> The EDRN High Risk Registry (HRR)recruits individuals that carry germline mutations for hereditary cancer syndromes, who are willing to participate in biomarker studies.  Recruitment is pursued through distribution of recruitment packets.  The recruitment packet includes a cover letter, EDRN HRR brochure, consent form, HIPAA authorization, and baseline questionnaire.  Upon completion of enrollment materials, each Registry member is provided a Certificate of Confidentiality, which has been issued by the NCI for the EDRN HRR. The EDRN HRR has a website (http://medicine2.creighton.edu/EDRN-Registry). It provides eligibilty, enrollment educational information for individuals who are at high risk of developing hereditary cancer.  The EDRN HRR newsletter is published twice each year.  These are distributed to EDRN HRR members on an annual basis.

Follow-up questionnaires are sent to Registry participants each year. An EDRN HRR database has been established to store demographic data, personal and family history of cancer diagnoses, personal smoking history, female specific history, as well as cancer prevention, detection and treatment information collected on questionnaires.  All EDRN HRR questionnaires and database use the EDRN CDEs. </_3:objective>
    <_4:title>Early Detection Research Network Registry for Hereditary Cancer</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174, 153, 155, 183, 157, 154                                                                        </_3:cancerType>
    <_3:abbreviatedName>EDRN Registry for Hereditary Cancer</_3:abbreviatedName>
    <_3:aims>To maintain and expand our High Risk Registry of carriers of cancer genetic syndromes who are willing to participate in biomarker studies.  </_3:aims>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/95">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/93"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Biomarker Development Laboratory</_3:abbreviatedName>
    <_4:title>Biomarker Development Laboratory</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>183, 185                                                                                            </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/93"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/281">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/428"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/420"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/429"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/446"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/426"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/142"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/424"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/429"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Canary TMA</_3:abbreviatedName>
    <_3:startDate>Feb 24 2009 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Mar 23 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Canary TMA</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:phasedStatus>1</_3:phasedStatus>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/279">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/515"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:estimatedFinishDate>Mar 25 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:abbreviatedName>Lung Cancer Specimen Reference Set A (Full) Application:  Hirschowitz - University of Kentucky (2009</_3:abbreviatedName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>See Lung Reference Set A</_3:eligibilityCriteria>
    <_3:startDate>Mar 26 2009 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:blinding>Samples were blinded at NCI-Frederick</_3:blinding>
    <_3:aims>Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/515"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/239"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Lung Cancer Specimen Reference Set A (Full) Application:  Hirschowitz - University of Kentucky (2009)</_4:title>
    <_3:objective>We are continuing validation with two advanced objectives: 1) To evaluate assay performance for established lung cancer diagnosed in a clinical population 2) to confirm results that indicate this marker set may detect cancer and predict the onset of NSCLC prior to radiographic detection in a screened population.</_3:objective>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>150 cases and 150 high risk controls w/lesions - Lung Set A pre-validation</_3:plannedSampleSize>
    <_3:dataSharingPlan>Lab Data will be analyzed by the DMCC and shared according the LCBG/NCI guidelines</_3:dataSharingPlan>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/229">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/124"/>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/124"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles</_3:abbreviatedName>
    <_3:startDate>Mar  1 2004 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>189                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Oct  1 2006 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/124"/>
    <_4:title>Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>Tissue, serum, and urine from 200 patients undergoing partial or radical nephrectomy for renal cell carcinoma</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/283">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/118"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>BRSCW Applicant: Diamandis (2007)</_3:abbreviatedName>
    <_3:startDate>Apr  2 2007 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Apr  1 2008 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>BRSCW Applicant:  Diamandis - Mt Sinai (2007)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>Pooled Ovarian Reference Set</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/258">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/187"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>A Methylation Panel for Bladder Cancer</_3:abbreviatedName>
    <_3:startDate>Jan  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>1                                                                                                   </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2008 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_4:title>A Methylation Panel for Bladder Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/191">
    <_4:title>Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN</_4:title>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_4:description>This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers.  The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer.  These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory.  In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis.  Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins.  Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.</_4:description>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:dataSharingPlan>These data may be used as a valuable source for evaluating biomarker candidates within EDRN.  Our vision is to make the protein lists, and their quantitative information, available to the EDRN researchers (prior to publication by our group) so that researchers may interrogate the data for information supporting specific biomarkers of interest to them. All resulting data will be deposited on a secure site with permissions given to EDRN ovarian cancer researchers, or any other researcher involved in EDRN, under the direction of the DMCC.  Data will be housed on the FHCRC (McIntosh laboratory) CPAS installation (Rauch et al 2006).  Details of the specific use of the system for data mining can be found at the site, but the figure below provides an example of what the resource will look like to those who make use of it.  In this screen-shot, the results of a protein query for APOA4 is displayed.  The display shows whether or not the protein was found, provides gene and protein aliases (which accomodate the non-standard manner in which genes and proteins are named), the overall sequence coverage found in the experiment, and specific protein and peptide ratio information for that protein. </_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/231"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers.  The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer.  These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory.  In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis.  Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins.  Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.  
This project intends to perform in-depth interrogation of these samples and also to stage these findings as part of a queryable database, which may be used by EDRN researchers.  The results will also be provided to the DMCC.  We also propose to provide consulting resources for the EDRN community who may wish to interrogate and interpret the data we are providing.
</_3:objective>
    <_3:startDate>Jan  2 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:aims>Our specific aims are to:

1)&amp;nbsp;&amp;nbsp;&amp;nbsp;Perform two comprehensive proteomic profiling experiments.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Diagnosed between two years and four months before diagnosis.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Diagnosed between four years and two years before diagnosis.
2)&amp;nbsp;&amp;nbsp;&amp;nbsp;Analyze and disseminate the raw and processed data.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Search data from pre-clinical specimens and combine with results from clinical specimens.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Stage and disseminate data on queryable system and make available to EDRN.
3)&amp;nbsp;&amp;nbsp;&amp;nbsp;Provide MS/MS data analysis and interpretation support to the EDRN, and cooperation with the DMCC.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Provide consulting with researchers who wish to interpret the resulting ovarian data.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Process and stage other MS/MS proteomic data identified by the EDRN for dissemination through the network and under the supervision of the DMCC. 
</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/231"/>
    <_3:abbreviatedName>Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN</_3:abbreviatedName>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>17 cases (specimen collected between four months and four years prior to clinical diagnosis), 17 matched controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/138">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>100 blood samples from lung cancer patients and 100 matching controls were randomly chosen in pairs from CARET. Each case and control pair was matched on age at enrollment (5-year intervals), sex, intervention arm (active vitamins or placebo), exposure population (asbestos or heavy smoker), baseline smoking status (active or former), year of enrollment, and year of blood draw.</_3:finalSampleSize>
    <_3:dataSharingPlan>shared after publication completed</_3:dataSharingPlan>
    <_3:finishDate>Aug  7 2007 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Natural Array technique</_3:analyticMethod>
    <_3:abbreviatedName>Lung CARET</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:bmName>Annexin, LAMR1, PGP</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1436"/>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_4:description>PURPOSE: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies which we have applied to lung cancer for discovery of novel antigens, and for validation in pre-diagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis.
MATERIALS AND METHODS: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1824 fractions were spotted in duplicate on nitrocellulose coated slides. The microarrays produced were utilized in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed subjects with lung cancer are associated with autoantibodies in sera collected at the pre-symptomatic stage and to determine whether additional antigens may be identified in pre-diagnostic sera. Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were hybridized to individual microarrays.
RESULTS: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis.
</_4:description>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>Disease status was blinded for batch 1, but was unblinded after analysis was done to determine if the findings are sufficiently promising to proceed with the rest of the CARET sera</_3:blinding>
    <_3:aims>Aim 1:  To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis.
Aim 2:  To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type.
Aim 3:  To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.</_3:aims>
    <_3:outcome>Annexin was significantly elevated in lung cancer patients in serum 0-12 months prior to diagnosis (p-value = 0.001) and the area under ROC curve 0.71 with 95% confidence interval from 0.63 to 0.78.  The direct clinical utility for Annexin in pre-clinical high risk (heavy smoker) population is unclear as the sensitivity at 90% specificity is 25%, or sensitivity 55% at 80% specificity.  However, this validated marker could serve as a member in a panel, yet to be formed, to reach clinical utility for early detection of lung cancer.

Lung cancer reference set A specified a PPV of 2.5% would be clinically significant assuming lung cancer incidence among heavy smokers is 1% per year. If we apply 25% sensitivity at 90% specificity in this study, PPV is 2.5%. Note that CARET specimens used in this study were collected within 12 month prior to diagnosis, not at diagnosis. This indicates potential use of Annexin to enrich the high risk smokers for further screening (e.g. CT), though the enrichment is a moderate 2.5 folds. Given Hanash Lab using specimens at diagnosis observed 40-50% sensitivity with near 100% specificity, it seems that the diagnostic performance of Annexin improves as time near diagnosis. Therefore, it is recommended that Annexin should also be validated for it?s potential clinical use for aiding diagnosis among patients having suspicious lesions in lung (lung cancer reference set B).

PGP was not significantly associated with lung cancer in pre-clinical serum.

Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens
</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/492"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques</_4:title>
    <_3:objective>1.1    To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status.

1.2   To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody.

1.3   To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
</_3:objective>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>100 blood samples from lung cancer patients and 100 matching controls</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/226">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>At the end of the study, each site is responsible for reporting the status of all cases to the DMCC and NCI.</_3:dataSharingPlan>
    <_3:blinding>The contract laboratory responsible for urine sediment DNA isolation and the investigators performing qMSP will be blinded to all participant urinalysis, cytology, cystoscopic and pathology results to minimize bias.</_3:blinding>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/187"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.</_3:analyticMethod>
    <_3:abbreviatedName>BLADDER-PRE-VAL</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>Eligible subjects will be patients who have been referred for cystoscopy to evaluate microhematuria, voiding dysfunction or others concerns.
A) Inclusion criteria include:
1. Patient who is schedule to undergo cystoscopy as indicated in the evaluation of a specific urological condition (eg hematuria or voiding dysfunction)
2. Patient who is willing and able to provide a voided urine specimen for the study.
3. Patient who has signed informed consent
a. allowing processing/evaluation of urine for biomarker evaluation including DNA studies
b. allowing access of the research staff to the patient&amp;#39;s medical record e.g. to determine if bladder cancer diagnosed at cystoscopy or thereafter
B. Exclusion criteria include:
1. Patient not willing to sign informed consent
2. Patient unable to provide a voided urine sample
3. Previously treated malignancy
4. Previous recontructive genitourinary surgery (for example prior prostatectomy in men or augmentation cystoplasty in women would confound urinary methylation marker analysis)
5. Previous pelvic irradiation
6. Previous intravesical pharmacotherapy (eg BCG or DMSO)
7. Presence of urinary infection
8. Indwelling urinary catheter or stent

A. Cases are subjects whose cystoscopry or related clinical testing (eg biopsy pathology or urine cytology) indicates presence of transitional cell carcinoma.
B. Controls are subjects who are not found to have urothelial cancer after cystoscopy, biopsy pathology or urine cystology.
C. Participating subjects found to have non-transitional cell carcinoma (eg squamous cell carcinoma or adenocarcinoma) will be evaluated separately for the cases and controls, eg methylation will be studied for descriptive purposes but excluded from case-controls comparison.
</_3:eligibilityCriteria>
    <_3:startDate>Feb  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_4:description>This is a pre-validation study of a new diagnostic test for gene methylation analysis for bladder cancer.
Three groups will be included in this study.  The first group will include 50 patients with pathologically confirmed bladder cancer (20 low grade papillary, 10 high grade papillary and 20 muscle-invasive).  The second and third groups together will include 100 (50 each group) participants without bladder cancer and will serve as control groups.  Control Group 1 will include 50 participants requiring cystoscopy for hematuria.  Control Group 2 will include 50 participants requiring cystoscopy for foreign body (urinary stones, stents, and catheters) or infection.  Both control groups are required to be negative for bladder cancer after cystoscopy. 
The contract laboratory responsible for urine sediment DNA isolation and the investigators performing qMSP will be blinded to all participant urinalysis, cytology, cystoscopic and pathology results to minimize bias. 
We proposed to prevalidate a panel of 5 known methylated genes in a cohort of patients diagnosed with bladder cancer and with benign disorders of the lower urinary tract to assess the sensitivity and specificity of the methylated genes and to identify the most optimal panel of methylated gene markers and effective technology to inform a future, more definitive, validation study.</_4:description>
    <_3:aims>This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer.

This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/121"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/125"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/119"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/136"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/587"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/510"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/187"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/111"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Methylation &amp; Proteomics-Based Detection of Bladder Cancer</_4:title>
    <_3:objective>To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated gene markers, in detecting bladder cancer in participants pathologically confirmed to have this disease.

Secondary objective: to test the sensitivity and specificity of an Aurora A FISH probe for the detection of clinically evident bladder cancer.</_3:objective>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>50 bladder tumor cases; 75 cystoscopy for hematuria controls; 75 cystoscopy for foreign body or infection controls</_3:plannedSampleSize>
    <_3:fieldOfResearch>Hypermethylation</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/190">
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1365"/>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1366"/>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/230"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement</_3:abbreviatedName>
    <_3:startDate>Jan  2 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:estimatedFinishDate>Dec 31 2008 12:00AM</_3:estimatedFinishDate>
    <_3:finalSampleSize>Not yet determined.  Still open.</_3:finalSampleSize>
    <_3:analyticMethod>Various including quantile regression, Fishers exact, binomial proportion and others.  The methods are not yet fixed because we are still in discovery.</_3:analyticMethod>
    <_3:objective>The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types.  Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors</_3:objective>
    <_3:bmName>Broad based screen of possible biomarkers.  p53 is included here.</_3:bmName>
    <_3:aims>1.B. Project Objectives
Aim 1:  Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53.

Aim 2:  Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera.
a.Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies.
b.Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies
c.Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies
d.Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera.
e.Determine if mutation-specific antibodies can distinguish tumor types.
</_3:aims>
    <_3:cancerType>174, 183, 185                                                                                       </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/230"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_4:title>Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>100 early-stage breast cases, 100 early-stage prostate cases, 15 early-stage ovarian cases,
250 breast cases, 250 matched controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/139">
    <_3:collaborativeGroupText> </_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Familial MM</_3:abbreviatedName>
    <_4:title>Biomarkers in Familial Multiple Myeloma</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>                                                                                                    </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/79">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Identification of protein and genetic biomarkers of prostate cancer</_3:abbreviatedName>
    <_4:title>Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/90">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Protein profiling for detection of high risk breast cancer</_3:abbreviatedName>
    <_4:title>Protein profiling for detection of high risk breast cancer</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/90"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/320">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Follow EDRN guidelines for public sharing upon completion</_3:dataSharingPlan>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>7.1&amp;nbsp;&amp;nbsp;&amp;nbsp;Vimentin methylation (Colosure)
This assay will be performed at LabCorp under a sublicense from Exact Sciences according to previously published method described in the background.  Assay qualitatively tests for presence of methylated vimentin gene.  Result is positive or negative.  The vimentin methylation assay will be performed blinded without knowledge of clinical source or results of other assays. 
7.2&amp;nbsp;&amp;nbsp;&amp;nbsp;Fecal immunochemical Test (FIT)
The FOBT-CHEKOC, Polymedco, Inc product will be used according to manufacturer?s instructions.  The threshold for a positive test is 100 ng/ml. The Central Biomarker Laboratory will process the samples using equipment provided by Polymedco, Inc.  Technicians will undergo tutorial and quality assessment with Polymedco, Inc support technicians prior to study launch.  A quantitative result will be generated and recorded in the database.  If either stool result is above Polymedco, Inc recommended cut-off, that subject will be called positive. 
7.3&amp;nbsp;&amp;nbsp;&amp;nbsp;Galectin-3 Ligand
The analytically validated ELISA method described in the preliminary data will be transferred to an EDRN Biomarkers Reference Laboratory.  Serum aliquots will be provided to the analytical sites in a blinded fashion. The Bresalier laboratory will assay 20% of the samples to ensure quality control. All of the samples will be assayed by the Biomarker Reference Laboratory that will be selected by the NCI-EDRN program staff.
7.4&amp;nbsp;&amp;nbsp;&amp;nbsp;Exact Sciences DNA Stool Biomarker Panel:  Potential improved Exact Sciences DNA Stool Biomarker Panel
The Exact Sciences panel consists of a panel of genetic biomarkers from DNA isolated from human stool.  The panel consists of:
1. qInvader (an automated, multiplexed rtPCR assay) reactions of:
a.  methylated vimentin and MM2 multiplexed
b.  K-Ras multiplex, 1 amplicon, 7 mutations
c. APC panel 1, 3 amplicons, 3 mutations.
d. APC panel 2, 3 amplicons, 3 mutations
2. Immuno-hemoglobin (ELISA based) assay or stool supernatant.
</_3:analyticMethod>
    <_3:abbreviatedName>GLNE 010 - Colon Validation Study</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Jul 31 2015 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>Galectin-3 Ligand, Vimentin methylation (Colosure), FOBT-CHEKOC, Polymedco, Inc for Fecal Immunochemical Test (FIT) and Exact Sciences DNA Stool Biomarker Panel:  Potential improved Exact Sciences DNA Stool Biomarker Panel.</_3:bmName>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:eligibilityCriteria>5.2&amp;nbsp;&amp;nbsp;&amp;nbsp;Eligibility 
5.2.1&amp;nbsp;&amp;nbsp;&amp;nbsp; Inclusion Criteria
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Adults 50-80 and undergoing a colonoscopy defined as:
o&amp;nbsp;&amp;nbsp;&amp;nbsp;First time screening or a surveillance procedure  
o&amp;nbsp;&amp;nbsp;&amp;nbsp;No complete colon exam (colonoscopy or CT colonography) within 3 years except as noted. (see section 5.4.1)  
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to sign informed consent 
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Able to physically tolerate removal of up to 50 ml of blood
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to collect 2 stool samples 
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to collect 150 ml of urine

5.2.2&amp;nbsp;&amp;nbsp;&amp;nbsp;Exclusion Criteria
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Inability to provide informed consent
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;History of Inflammatory Bowel Disease
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Overt rectal bleeding within (including due to suspected hemorrhoids).
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Positive guiaic-based occult blood or fecal immunochemical test (e.g. FOBT, FIT) in the past 12 months.
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Undergone resection of the colon for any indication
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Subjects with known HIV or chronic viral hepatitis (Hepatitis B and C)
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Subjects with known or suspected HNPCC (Lynch Syndrome) or FAP
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Any cancer  within 5 years of enrollment except any of the following: 
o&amp;nbsp;&amp;nbsp;&amp;nbsp;Squamous cell carcinoma of the skin or Basal cell carcinoma of the skin
o&amp;nbsp;&amp;nbsp;&amp;nbsp;Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only.  (Excluded if had pelvic radiation) 
o&amp;nbsp;&amp;nbsp;&amp;nbsp;Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
</_3:eligibilityCriteria>
    <_3:startDate>Aug  1 2010 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>All specimens will be blinded by the DMCC</_3:blinding>
    <_3:aims>Aim 1
a. To estimate the sensitivity and specificity for 1) colorectal adenocarcinoma and high grade dysplasia, or 2) screen relevant neoplasms (colorectal adenocarcinoma, high grade dysplasia, and adenomas&amp;#062;1cm) of the following individual colorectal neoplasia early detection biomarkers using colonoscopy as the gold standard:
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;stool vimentin methylation
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;serum galectin-3 ligand, 
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;fecal immunochemical tests (FIT) 
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Exact Sciences stool DNA panel
&amp;#149;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other currently unspecified biomarkers 

b. To test the null hypotheses that the sensitivities are 50% or lower versus the alternative hypotheses that sensitivities are higher than 50% for the early detection of colorectal adenocarcinoma and high grade dysplasia; and the null that sensitivities are 25% or lower versus  the alternative that they are higher than 25% for the detection of screen relevant neoplasia, using colonoscopy as the gold standard and  for both outcomes, to test the null hypotheses that the specificities of the above early detection biomarkers are 70% or lower versus the alternative hypotheses that specificities are higher than 70%.

Aim 2: To determine if the sensitivities of the above early detection biomarkers are greater than that for fecal immunochemical testing (FIT) for the detection of the combined endpoint of colorectal adenocarcinoma or adenomas with high grade dysplasia. 

Aim 3
a. To estimate the sensitivity and specificity of the above individual binary biomarkers, in combination with FIT for 1) colorectal adenocarcinoma and high grade dysplasia, and for 2) screen relevant neoplasms (SRN). The combinatory rule defines a test positive if either individual test is positive.

b. To test the null hypothesis that the sensitivities of the combined tests described Aim 3a are equal or lower than a minimally acceptable value (MAV) versus the alternative that they are higher than the MAV, with the MAV set as 70% for the detection of colorectal adenocarcinoma and high grade dysplasia and 45% or higher for SRN with the assumption that the specificity is maintained at 70% or higher using colonoscopy as the gold standard. 

c. To construct a combined early detection biomarker score using the above individual biomarkers using logistic regression, and describe its performance for 1) colorectal adenocarcinoma and high grade dysplasia, and for 2) SRN.

Aim 4
To establish an archive of appropriately preserved stool, serum, plasma, urine, and DNA human biospecimens to be used by EDRN investigators for future validation and biomarker discovery research.

</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>Validation of Biomarkers for the Early Detection of Colorectal Adenocarcinoma</_4:title>
    <_3:objective>We propose a Phase 2 (large cross-sectional) PRoBE-compliant validation trial of stool-based and serum-based tests for the detection of colorectal neoplasia  (1).  The trial is powered to detect early stage colorectal adenocarcinoma or high grade dysplasia.  This is the most stringent, conservative approach to the early diagnosis of colonic neoplasia and addresses the most important endpoint of identifying individuals with curable, early stage cancer and those with very high risk non-invasive neoplasia (high grade dysplasia).</_3:objective>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>6000 colonoscopy patients</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/136">
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:dataSharingPlan>Data will be sent to DMCC for analysis, and shared with EDRN once analyzed and public once published.</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/176"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>MESOTHELIOMA</_3:abbreviatedName>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:bmName>SMRP and OPN</_3:bmName>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:blinding>All specimens will be blinded.</_3:blinding>
    <_3:aims>Phase I: - Identification and assemblage of representative cohorts of individuals with MM, no malignancies but increased risk for MM due to asbestos exposure, and (optionally) lung malignancies other than MM
Phase II (A) - Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals with a clinical diagnosis of malignant mesothelioma from individuals who are asbestos-exposed but without a clinical diagnosis of malignant mesothelioma.
Phase II (B) ? Determine the comparability of analyte values across contributing centers and determine covariates that influence analyte levels
Phase II (C) ? Determine the sensitivity and specificity of SMRP and OPN, alone and in combination, in distinguishing individuals with MM from those without.
Phase III.  Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals who would subsequently develop malignant mesothelioma from matched individuals who did not subsequently develop malignant mesothelioma.
Phase IV.  Determine the sensitivity and specificity of SMRP and OPN in other populations of interest.</_3:aims>
    <_3:analyticMethod>The form of the final analysis will not be determined until the end of Phase II (B).  To arrive at an initial estimate of the power for this phase, we analyze the power we would have if the data from all contributing sites can be combined and there are no covariates that will need to be included in the analysis.  With a total of 164 cases and 687 controls, using 80% power and with a 2-sided, 0.05-level test, the following tables show the differences in sensitivity and specificity that are detectable:
Table 1.  Sensitivity detectable with 80% power in a joint analysis of sensitivity and specificity
Null Hypothesis Sensitivity 0.10 0.25 0.50 0.75
Detectable Sensitivity&amp;nbsp;&amp;nbsp;&amp;nbsp;0.18 0.36 0.62&amp;nbsp;&amp;nbsp;&amp;nbsp;0.85

Table 2.  Specificity detectable with 80% power in a joint analysis of sensitivity and specificity
Null Hypothesis Specificity 0.50 0.80 0.90 0.95
Detectable Specificity&amp;nbsp;&amp;nbsp;&amp;nbsp;0.52 0.85 0.94&amp;nbsp;&amp;nbsp;&amp;nbsp;0.98

</_3:analyticMethod>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/499"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/176"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/498"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/84"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/456"/>
    <_4:title>Soluble  Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>652 controls and 165 cases</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/119">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>160 cases, 160 benign disease controls, 480 general population controls</_3:finalSampleSize>
    <_3:dataSharingPlan>Study results will become available upon publication completion.</_3:dataSharingPlan>
    <_3:secureOutcome>Results will be posted after publication.</_3:secureOutcome>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Based upon comprehensive reviews of ovarian cancer biomarkers and preliminary studies in which multiple biomarkers have been compared simultaneously, investigators representing Ovarian Cancer SPORES, EDRN and the PLCO trial are working towards defining a consensus panel of biomarkers appropriate for ovarian cancer screening.  Towards this goal, SPORE and EDRN investigators proposed to assemble a new set of phase II specimens (160 ovarian cancer cases with pre-operative bloods over-sampled for early-stage disease, 160 benign disease controls, 480 general population controls, and serial samples collected one year apart from 40 healthy women).  The top 5 markers identified in preliminary work by Boston-NW and FHCRC investigators, plus an expanded panel of Luminex markers, were evaluated to identify a final consensus panel of 5 to 15 biomarkers.  CA125 and the top 5 new markers were measured by standard ELISA using an automated platform, or kit, at BWH.  CA125 and the top 5 new markers, as well as additional candidate markers unique to each institution, were measured using Luminex at FHCRC and Pittsburgh. Results from ELISA were compared to results obtained from Luminex to evaluate the consistency of CA125 and the top 5 new markers across platforms and institutions.  Markers were selected for inclusion in the panel based on their individual performance, their contribution to a panel, and their stability over time, where the last predicts the improvement in performance expected from their use in a longitudinal algorithm. 
For markers that could be measured adequately on Luminex, to preserve specimen volume, the Luminex platform was used to evaluate the final consensus panel in the requested PLCO specimens; standard ELISA were used only if necessary due to inadequate measurement by Luminex.  </_3:analyticMethod>
    <_3:abbreviatedName>OVAR-VAL-PRE-PLCO</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Aug  1 2007 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>FHCRC: CA125, HE4, Mesothelin (SMRP), SLPI , Spondin, Cadherin-6, B7-H4, CD-24, IGF2, CHI3L1, DcR3, CA15-3, CA72-4, CA19-9.  MD Anderson: Hepcidin, ITIH4, CTAPIII, B2-microglobulin, Transferring, Transthyretin, apolipoprotein A1.  Pittsburgh: CA125, Prolactin, MIF, TSH, IGF-BP1, CYFRA21.1, Eotaxin, sVCAM-1, MMP-2, IL-6, IL-2R, IL-8, EGFR, GH, Leptin.  MGH: CA125, CA72.4, CA19.9, CA15.3, CEA, HE4, SMRP, B7-H4, DcR3, Spondin-2, IGF-2, CHI3L1.</_3:bmName>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_4:description>Phase II specimens from 160 ovarian cancer cases and 640 benign disease or general population controls were assembled from four Early Detection Research Network (EDRN) or Ovarian Cancer Specialized Program of Research Excellence (SPORE) sites and used to rank 51 biomarkers.  Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40.</_4:description>
    <_3:startDate>Aug 15 2005 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>All samples were blinded at FCCC</_3:blinding>
    <_3:aims>1. Retest all of the biomarkers that have performed well in preliminary studies in a newly-assembled test set of 160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls. 
2. Evaluate the reproducibility, concordance with standard ELISA, and performance of the bead-based (Luminex) assays. 
3. Identify a consensus panel comprising the biomarkers that are most informative on their own as well as those that are most complementary when used together, and that can be evaluated in no more than .3 ml of serum using the Luminex platform, and up to 5 additional markers that can be measured adequately only by standard ELISA.  </_3:aims>
    <_3:outcome>Results will be posted after publication.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/238"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/531"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/235"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/236"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/237"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/246"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/231"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study</_4:title>
    <_3:objective>Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a ?working consensus panel? for subsequent analysis in PLCO specimens. </_3:objective>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>160 Ovarian Cases (80 early stage &amp; 80 late stage); 160 benign disease controls; 480 general population controls;  40 serial samples</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Hypermethylation</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/97">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Early detection of liver cancer and hepatitis</_3:abbreviatedName>
    <_4:title>Early detection of liver cancer and hepatitis</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/249">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/454"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/454"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/251"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008)</_3:abbreviatedName>
    <_4:title>Colon Cancer Specimen Reference Set Application: Disis - University of Washingon (2008)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/454"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>Serum from 50 participants with colon adenocarcinoma; 50 with colonic adenomas; and 50 with an endoscopically normal colon.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/55">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Detection of Serum Markers of Breast Cancer by SELDI</_3:abbreviatedName>
    <_4:title>Detection of Serum Markers of Breast Cancer by SELDI</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/259">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/234"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/158"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group, Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>The Early Detection Research Network: Biomarker Reference Laboratories</_3:abbreviatedName>
    <_3:startDate>Sep  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>4, 12, 16                                                                                           </_3:cancerType>
    <_3:estimatedFinishDate>Aug 31 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_4:title>The Early Detection Research Network: Biomarker Reference Laboratories</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/96">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Identification of New Markers in Normal and Abnormal Pap Smears</_3:abbreviatedName>
    <_4:title>Identification of New Markers in Normal and Abnormal Pap Smears</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>180                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/247">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/162"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/162"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/251"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006)</_3:abbreviatedName>
    <_4:title>Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006)</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/162"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/62">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/150"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/150"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>National Ovarian Cancer Early Detection Program Blood and Genetics</_3:abbreviatedName>
    <_4:title>National Ovarian Cancer Early Detection Program Blood and Genetics</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/150"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/104">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Assessment of Clinical Potential of Digital SNP Analysis</_3:abbreviatedName>
    <_4:title>Assessment of Clinical Potential of Digital SNP Analysis</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174, 162, 172                                                                                       </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/123">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Novel Surveillance HNPCC</_3:abbreviatedName>
    <_4:title>Novel Surveillance Strategies For Hereditary Nonpolyposis Colon Cancer Family Members</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/322">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/260"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/260"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/134"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Liver Ref Set: Lubman (Rapid #2) - Univ of Mich</_3:abbreviatedName>
    <_3:startDate>Sep 15 2010 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Liver Reference Set Applicant (Rapid #2): Lubman - Univ of Michigan</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/318">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>estimated at ~250</_3:finalSampleSize>
    <_3:dataSharingPlan>Data shared through public EDRN database one year after study completion</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/578"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The results of these assays will determine whether
statistically significant associations between disease status in the prostate (no disease, BPH, PCa with or without concomitant BPH) and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed among patients with low but detectable serum PSA. If so, then ROC analyses will determine whether the sensitivity and specificity of these protein levels to ?predict? disease status are superior to those of PSA or other similarly evaluated biomarkers as reported in the literature. If so, a larger, multiinstitutional study to validate these findings across a broader patient population will be pursued through collaborative efforts within the NCI-sponsored Early Detection Research Network (EDRN) to validate these findings. Conversely, if no statistically significant associations between disease status in the
prostate and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed, then we will conclude that these proteins do not comprise suitable biomarkers for disease status in the prostate, and that further studies are not warranted.</_3:analyticMethod>
    <_3:abbreviatedName>Chemokine Prostate Cancer Biomarkers</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/578"/>
    <_3:estimatedFinishDate>Sep 30 2011 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>CXCL5 and  CXCL12</_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>To-date, through the efforts of Co-Investigator Dr. John Wei in the Department of Urology, the University of Michigan EDRN has procured serum, plasma and urine from &amp;#062;1000 men referred to Dr. Wei with an indication for prostate biopsy. Of these, only 37.5% exhibit malignant glands on one or more needle biopsies. This is perhaps not surprising, as the majority (70%) of men referred for needle biopsy exhibit pre-biopsy PSA values of &amp;#060;10ng/ml, which, as described above, are not diagnostic for PCa. Taken together, these studies show that low serum PSA and other recently developed biomarkers cannot reliably distinguish between PCa and BPH or indicate which patients should, or should not, undergo diagnostic needle biopsy. Therefore, it is desirable to develop
and validate suitable biomarkers that could be used alone or in conjunction with PSA to distinguish patients at high risk for PCa who should undergo diagnostic needle biopsy from those
at low risk who could benefit from watchful waiting. </_3:eligibilityCriteria>
    <_3:startDate>Oct  1 2009 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>STUDY DESIGN
1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers to distinguish between patients at high-risk versus low-risk for harboring prostate malignancies. However, this pilot and feasibility study utilized a very small sample size of 51 patients, which limited the ability of this study to adequately assess certain technical aspects of the ELISA technique and statistical aspects of  we propose studies designed assess the robustness (Specific Aim 1) and predictive value (Specific Aim 2) of these markers in a larger study population.
2. ELISA Assays. Serum, plasma, or urine chemokine levels are assessed using 50 ul frozen specimen per sandwich ELISA in duplicate using the appropriate commercially-available capture antibodies, detection antibodies, and standard ELISA reagents (R&amp;D Systems), as we have described previously (15, 17, 18). Measures within each patient group are regarded as biological replicates and permit statistical comparisons between groups. For all ELISAs, a standard curve is generated with the provided standards and utilized to calculate the quantity of chemokine in the sample tested. These assays provide measures of protein concentration with excellent reproducibility, with replicate measures characterized by standard deviations from the mean on the order of &amp;#060;3%.
</_4:description>
    <_3:aims>SPECIFIC AIMS/DELIVERABLES. In order to test this hypothesis, we will accomplish two Specific Aims:
Specific Aim 1. Assess the robustness of serum, plasma, or urine measures of CXCL5 and CXCL12.
Specific Aim 2. Determine whether serum, plasma, or urine levels of CXCL5 and CXCL12 provide
sufficient predictive value for prostate cancer among men with low (&amp;#060;10ng/ml) total serum PSA.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/578"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Chemokine Prostate Cancer Biomarkers</_4:title>
    <_3:objective>CXCL5 is a pro-angiogenic CXC-type chemokine that is robustly secreted by prostate cancer cells. Tissue microarray analyses have demonstrated that CXCL5 protein expression levels are concordant with prostate tumor progression. Biological assays have demonstrated that CXCL5 promotes both the proliferation and invasiveness/metastasis of prostate cancer cells. CXCL12 is also a pro-angiogenic CXC-type chemokine expressed in bone marrow stroma and tumor endothelium that ?guides? invasive prostate cancer cells to establish metastatic tumors in bone. Prostate
cancer cells up-regulate protein expression of CXCR4, the CXCL12 receptor, concordantly with prostate tumor progression in response to increasing levels of tumor stromally-secreted CXCL12. Preliminary studies from our laboratory have shown that, among 51 men with low (&amp;#060;10ng/ml) serum PSA values, both serum CXCL5 and serum CXCL12 levels were significantly higher among men who were biopsy-positive compared to those who were biopsy-negative for prostate cancer. These studies also showed that serum CXCL5 levels distinguished cancerous from non-cancerous large volume prostates, whereas CXCL12 accomplished the same for small volume prostates. Based on these preliminary data, we hypothesize that serum, plasma, and urine levels of CXCL5 and CXCL12 can distinguish between men with cancerous or non-cancerous prostates. In order to test this hypothesis, we propose two specific aims intended to assess the robustness and predictive value of these markers.</_3:objective>
    <_3:comments>Aim 1 is completed, Aim 2 is in prcess</_3:comments>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>~400</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/113">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Expression-based profiling</_3:abbreviatedName>
    <_4:title>Development of paraffin-based expression profiles to predict minimal vs. substantial risk of disease progression using retrospective datasets</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/36">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms</_3:abbreviatedName>
    <_4:title>Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/68">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Body Fluids as a Source of Diagnostic Biomarkers: Breast</_3:abbreviatedName>
    <_4:title>Body Fluids as a Source of Diagnostic Biomarkers: Breast</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/110">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Data will be shared upon completion of publication</_3:dataSharingPlan>
    <_3:finishDate>Feb  1 2007 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The DMCC will apply the boosting decision tree,11 the boosting logistic regression13, and other classification methods to identify a classification algorithm that has minimum Cross-Validation error. The performance of this classifier will be assessed with the following the intended clinical uses in mind: 1)For men with PSA &amp;#062; 4, the population by current practice undergone biopsies with 25% Positive Predicted Value (PPV) for positive biopsies, we could judge that the new test has clinical potential if on this population sensitivity is significantly better than 85% and specificity is significantly better than 50% (null hypothesis corresponding to PPV=36%). This question is answered by comparing the biopsy-negative non-cancer controls with each of two cancer groups (Gleason Score &amp;#060; 7, and 7 or greater), and combined. In order for the Phase II validation study has adequate power (85%), the target observed specificity for this classifier in training sample should be at least 65% at sensitivity fixed at 95% on ROC curve for all prostate cancers (Aim 1: two case groups combined and compared to controls). Aim 2 (Gleason 7 or greater prostate cancers compared to control and low grade prostate cancer groups combined) is considered as secondary because using Gleason Score 7 or greater as the cutoff point for high grade is more for feasibility rather reason (there are not enough prostate cancers with Gleason Score 8 or 9). 2) If the criterion for Aim 1 is satisfied, validation part of Phase II will proceed. If the observed sensitivity and specificity are significantly better than the values specified by null hypotheses but less than the target values, the study group will evaluate whether the observed performance still has potential clinical benefit, and if it does, whether to increase sample size for the validation part of Phase II.</_3:analyticMethod>
    <_3:abbreviatedName>SELDI-2</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Sep 29 2005 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>proteomics pattern</_3:bmName>
    <_3:publications rdf:resource="http://edrn.nci.nih.gov/data/pubs/1056"/>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:startDate>Apr 19 2004 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>All samples were blinded at EVMS.</_3:blinding>
    <_3:aims>The overall goal of Phase II is to develop and evaluate an algorithm for classifying cases and controls using protein profiles produced from SELDI-TOF-MS using serum collected from prostate cancer cases and non-cancer controls.
Objective 1 - Identification of biorepositories
Objective 2 - Generate protein profiles
Objective 3 - Construction of classifiers and development of algorithm.
Objective 4 ? Validate the classifier constructed in Objective 3.  If Objective 3, Aim 1, is successfully met</_3:aims>
    <_3:outcome>A number of challenges arose during the validation study. One was the time required to collect the needed samples. Although at the study onset, it was anticipated that 6 months would be required for samples collection, due to (a) dissimilar rates of each sample type (e.g., cancer, biopsy negative control, inflammation, etc.), (b) sample-matching challenges, (c) requirements for adequate numbers of high-grade and lower grade tumors, and (d) the rigorous requirements for a range of samples across PSA levels, the sample acquisition ultimately required two years. Another challenge was a broken source on the SELDI-TOF-MS at UAB. This occurred concomitant with the destruction and shearing of the fan that spread metal fragments through the system, leading to unstable spectral patterns, it required several months to identify that the SELDI-TOF-MS source was the cause of the instability. Ultimately, daily QC procedures using a reference pooled serum sample allowed the team to recognize these issues and correct them prior to the initiation of the analysis stage. The final challenge occurring during the analysis of samples was a defective peptide calibration standard used for the first week of the study at EVMS. This calibration sample was derived from a defective manufacturer lot such that only 5 of the 7 peaks could be identified. This suboptimal standard was used for about 1/3 of the samples run at EVMS. Subsequently, this lack of uniform 7 peak standard data was solved by extrapolation of data across the study and was unnecessary when the wavelet analytical approach was employed.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/108"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/142"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>SELDI Validation Study Phase II</_4:title>
    <_3:objective>This project ?A Comprehensive Program for the Validation of Prostate Cancer Early Detection with Novel Protein Identification Techniques -- is divided into three phases.  The goal of Phase I was to assess the reproducibility and portability of Surface-Enhanced Laser Desorption and Ionization time-of-flight mass spectrometry (SELDI-TOF-MS) using protein profiles generated from serum.  Phase I was recently successfully completed at six institutions using a single source of pooled sera.   </_3:objective>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>500 prostate cancer cases (250 with aggressive/advanced disease and 250 with intermediate- or low-risk disease) as well as 250 prostate cancer controls (biopsy-negative with a range of PSA values).  An additional group of 50 patients with other cancers but no evidence of prostate cancer and 50 patients with various inflammatory diseases will also be examined.</_3:plannedSampleSize>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/193">
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/120"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Clinical information on the reference set samples has already been provided to the DMCC. Laboratory data generated from the PSA isoforms analyses will be transferred directly from the Access analyzers into an excel (or other to be determined data file) file. This file will be forwarded to the DMCC.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The primary outcome analysis is to calculate the sensitivity corresponding to 70% specificity, i.e. ROC(0.30), and performing hypothesis testing against a null hypothesis of sensitivity=40%, i.e. ROC(0.30)=0.40. 95% confidence intervals will be calculated for ROC(0.30) as well as for the threshold corresponding to 70% sensitivity.

The secondary outcome analysis is to calculate the specificity corresponding to 95% sensitivity and its threshold. Hypothesis testing will be conducted against the null hypothesis of specificity 5%. 95% confidence intervals will be calculated for ROC-1(0.95) as well as for the threshold corresponding to 95% sensitivity.

Other exploratory analyses will be performed to examine the complementary properties of %proPSA with other clinical variables (age, race, and family history, DRE) and other PSA derivatives (PSA and fPSA). Logistic regression with forward model selection will be used to combine the markers and clinical variables. The ROC curve of the predicted score will be plotted and compared to that of the model using clinical variables and existing PSA and its derivatives but without %proPSA. These analyses will be performed for the whole group, for the group with PSA 2-10 ng/mL, and for the group with PSA 2-10 ng/mL and without suspicious DRE.</_3:analyticMethod>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:objective>Primary Objective ?  To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies.</_3:objective>
    <_3:bmName>[-2]proPSA</_3:bmName>
    <_3:phasedStatus>2</_3:phasedStatus>
    <_3:startDate>Jan  2 2008 12:00AM</_3:startDate>
    <_3:protocolType>Validation</_3:protocolType>
    <_3:blinding>Specimens are blinded to investigators.</_3:blinding>
    <_3:aims>Secondary Objectives ? (1) To determine if [-2]proPSA is complementary to other PSA derivatives in a multi-marker model to improve the diagnosis and risk assessment of prostate cancer and reduce unnecessary biopsies, (2) To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies in truncated PSA ranges such as 2-10 ng/mL PSA and 2-4 ng/mL PSA, (3) To determine if the [-2]proPSA marker or a combination of markers studied can aid in the identification of aggressive cancers as determined by Gleason score.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Validation of [-2]proPSA for the Early Detection of Prostate Cancer</_4:title>
    <_3:abbreviatedName>proPSA</_3:abbreviatedName>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>200 positive biopsy cases, 300 negative biopsy controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/254">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer</_3:abbreviatedName>
    <_3:startDate>Jul  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/230"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/190"/>
    <_4:title>Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>60 cases, 60 controls + 50 (pre-op cases), 200 controls</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/60">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Clinical Validation of Molecular Signatures of Cervical Neoplasia</_3:abbreviatedName>
    <_3:startDate>Aug 12 1999 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>180                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Aug 13 2004 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_4:title>Clinical Validation of Molecular Signatures of Cervical Neoplasia</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/199">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/88"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/203"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>EDRN Pre-Validation of Multiplex Biomarker in Urine</_3:abbreviatedName>
    <_4:title>EDRN Pre-Validation of Multiplex Biomarker in Urine</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/188"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/241">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group, Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Integrated Development of Novel Molecular Markers</_3:abbreviatedName>
    <_3:startDate>Sep 30 2004 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>188, 162                                                                                            </_3:cancerType>
    <_3:estimatedFinishDate>Sep 29 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_4:title>Integrated Development of Novel Molecular Markers</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/256">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies</_3:abbreviatedName>
    <_3:startDate>Jun  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153, 154                                                                                            </_3:cancerType>
    <_3:estimatedFinishDate>May 31 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_4:title>Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/57">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Various assay techniques</_3:analyticMethod>
    <_3:estimatedFinishDate>Feb 28 2010 12:00AM</_3:estimatedFinishDate>
    <_3:abbreviatedName>Development and Evaluation of a Tumor Marker for Prostate Cancer</_3:abbreviatedName>
    <_3:bmName>EPCA-2, GSTPi, PSA, % free PSA, 2proPSA, BPSA, PBOV-1, JM-27, TSG, IL18, Endoglin (CD105), PCAM-1</_3:bmName>
    <_4:description>Major strides in the early detection, staging, monitoring, and risk stratification of men with prostate cancer have been realized over the last few decades.  We have recently witnessed a reduction in the death rate for prostate cancer, stage migration with increased numbers of men with local/regional disease, and a greater understanding of the natural history of progression following recurrence.  These advances, while not solely dependant on biomarkers, can be attributed to the discovery of Prostate Specific Antigen (PSA) in the late 1970&amp;#39;s.  In the wake of these discoveries, we still continue to unnecessarily biopsy men at risk for having prostate cancer to identify the 1:4 with the disease, understage men with presumed local disease, continue to lack an accurate method for staging which can direct treatment options for the individual patient and continue to poorly understand the tumor biology and kinetics of disease progression.  Clearly, discovery of a new tumor marker and validation/clinical investigation of the markers are mandatory to advance our knowledge and direct the care of men with prostate cancer.  With this research, we intend to evaluate the clinical, diagnostic, and prognostic accuracy of new and existing biomarkers on a prospective serum bank collected from men either participating in early detection programs or engaging in pre or post treatment situations.  By increasing our clinical research and specimen collections we hope to further advance the staging and direction for treatment in men with prostate cancer.

This study approaches patients scheduled for a prostate biopsy, patients visiting the Urology Outpatient Clinic with PSA elevation, patients scheduled for radical prostatectomy, prostate cancer patients with scheduled appointments in Radiation Oncology and men participating in early prostate cancer detection screenings. 

Subjects will be excluded from the study if:
1)  Subjects have any mental impairment that would hinder the ability to provide informed consent.
2) The subject has undergone a radical prostatectomy and is visiting the urology clinic for a follow up appointment.  We can not evaluate the protein profiles in the serum/urine for this group of patients because of prostate removal.  
3)  Subjects have had previous chemotherapy treatment.  Such treatments often induce oxidative damage that could affect protein expression. Therefore, such patients are excluded as their exposure histories may be confounded with respect to exposures relevant to prostate cancer.
4) The patient has had previous prostate surgery. These procedures will affect protein expression.
5)  Subjects have had previous cancer other than non-melanoma skin cancer.  Systemic oxidative DNA damage is suspected as a potential etiologic factor in a number of other cancers.  Therefore, such patients are excluded as their exposure histories maybe confounded with respect to exposures relevant to prostate cancer.

Upon receiving consent, urine and blood specimens are collected from the subjects.  The urine and blood are then processed and stored in our freezer bank.  This study represents little to no risk to the patient. Risks include mild pain and bruising which may result from the needle stick. There is a very small chance of infection.  There is also a very small chance that the patient may feel faint or pass out from the needle stick.  These are the usual risks associated with phlebotomy. Collection of the urine introduces no increased risk to the patient. Adverse experiences that are both serious and unexpected will be immediately reported by telephone to the Primary Investigator, Alan. W. Partin M.D., Ph.D., (410) 614-4876.
</_4:description>
    <_3:startDate>Apr  1 2000 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:blinding>All shared data is de-identified.</_3:blinding>
    <_3:aims>1) Collection and archiving of matched serum and urine specimens for biomarker research.  Collected from men who are in the early detection, diagnosis, treatment and monitoring stages for prostate cancer.  All specimens are available for collaborative research through proper EDRN/NCI- Investigator approval processes for EDRN purposes.

2)Participation in prospective EDRN coordinated pre-Validation and validation studies of several biomarkers for prostate cancer.  

3)Explore analyses of novel tumor marker technologies and multi-variable model development.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/83"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>Development and Evaluation of a Tumor Marker for Prostate Cancer</_4:title>
    <_3:objective>The primary objective is to work with the EDRN steering committee, the NCI administration, EDRN co-investigators, industrial partners and other biomarker scientists to further facilitate the rapid vertical evaluation and implementation of useful biomarkers into clinical practice.</_3:objective>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>1000 serum samples per year from healthy men</_3:plannedSampleSize>
    <_3:dataSharingPlan>Participation in ERNE- 
The overall goal of the EDRN Informatics Project, named the EDRN Resource Network Exchange (ERNE), is to develop network interfaces among databases for the purpose of sharing data of interest amongst EDRN investigators.  Our site was the first to go live across the internet and real time availability to our repository resources has been available for an entire year.  Through a secure network, EDRN investigators, via the DMCC, can query EDRN CDEs on all 4500 specimens collected at our CEVC.</_3:dataSharingPlan>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/94">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers</_3:abbreviatedName>
    <_4:title>Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/92"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/98">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Development of FISH-based assay for early detection of high grade cervical dysplasia</_3:abbreviatedName>
    <_4:title>Development of FISH-based assay for early detection of high grade cervical dysplasia</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>180                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/91"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/285">
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>50 HCC/50 Cirrhosis Controls</_3:finalSampleSize>
    <_3:dataSharingPlan>According to EDRN guidelines data will be shared through public portal.</_3:dataSharingPlan>
    <_3:finishDate>Mar 16 2009 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly.  The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage.  The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve &amp;#062; 90% sensitivity and &amp;#062; 85% specificity for the distinction of cirrhosis from HCC.  </_3:analyticMethod>
    <_3:abbreviatedName>Liver Reference Set (Rapid): Block (2008)</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Mar 17 2009 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>Sample Eligibility defined in DCP Protocol</_3:eligibilityCriteria>
    <_3:startDate>Apr 15 2008 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>We have developed a targeted glycoproteomic methodology that allows for the identification of glycoprotein biomarkers in serum. This simple methodology first identifies changes in N-linked glycosylation that occur with the disease. This change acts as a ?tag? so that we can extract out those specific proteins that contain that glycan structure. Our initial work in an animal model led to the discovery of a protein, GP73, which is 3 times more sensitive at detecting HCC than the current marker, AFP. In the animal model of HCC, the change in glycosylation was an increase in core fucosylation(Block et al. 2005). This change was also observed in people who developed HCC(Comunale 2006)</_4:description>
    <_3:blinding>All samples were blinded as part of the DCP protocol and then blinded during the sub-aliquot process at CLASS Lab</_3:blinding>
    <_3:aims>Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/66"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Liver Reference Set Application (Rapid): Block - Drexel Univ (2008)</_4:title>
    <_3:objective>The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis.  The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers</_3:objective>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/122">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed cancer.  Within 2 years, 17% had developed either a cancer or a pre-malignant lesion (e.g. adenoma).

Our goal is to recruit 265 mutation carriers from the EDRN High Risk Registry and Hereditary Cancer Center for the Longitudinal Serum Biorepository (LSB). Based on the cancer rates observed to date in the EDRN Registry, four years of follow-up in a group of this size would be expected to yield 53 invasive and in situ cancers and 37 benign premalignant lesions.

All subjects in the serum biorepository (1)have signed consent (2) are counseled carriers (APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6) and (3) are enrolled in family studies through CU&amp;#39;s Department of Preventive Medicine and/or are enrolled in the EDRN High Risk Registry.  Post specimen medical history is collected annually.

Serum and plasma are aliquoted for respository storage and stored in labeled cryovials in an ultra low temperature (-86C) freezer. Specimens in the LSB are available for use in EDRN biomarker development and validation studies.  </_3:objective>
    <_4:title>EDRN Longitudinal Serum Biorepository</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>174, 153, 155, 183, 157, 154                                                                        </_3:cancerType>
    <_3:abbreviatedName>LSB</_3:abbreviatedName>
    <_3:aims>To develop a longitudinal serum biorepository with annual serial samples collected from mutation carriers within the Hereditary Cancer Institute and High Risk Registry for retrospective evaluation of  promising biomarkers.</_3:aims>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/137">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>145 nonprogressors and 50 progressors</_3:finalSampleSize>
    <_3:abbreviatedName>BARRETT&amp;#39;S ESOPHAGUS</_3:abbreviatedName>
    <_3:finishDate>Mar  2 2009 12:00AM</_3:finishDate>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>The first step in evaluating a candidate marker is to show that there is a significant difference in the marker between cases and controls. If a marker is positive in only 5% of controls (i.e., 95% specificity), then this Project PI: Richard Sampliner, MD Principal Investigator/Program Director (Last, First, Middle): Gerner, Eugene W
sample size (100 cases and 200 controls) will provide over 90% power to detect a positivity rate in cases of 18% or greater, based on a two-group Fisher&amp;#39;s exact test at a two-sided 0.05 significance level. If a marker is positive in 10% of controls, then this sample size will provide over 90% power to detect a positivity rate in cases of 26% or greater. If a marker is positive in 25% of controls, then this sample size will provide over 90% power to detect a positivity rate in cases of 45% or greater. Looked at another way, if a marker is positive in
90% of cases (i.e., 90% sensitivity), then this sample size will provide over 90% power to detect a positivity rate in controls of 74% or lower. Given the exploratory nature of this study, a formal adjustment for multiple statistical comparisons is not planned; however, significance levels will be interpreted cautiously.</_3:analyticMethod>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:bmName>p16, RUNX3, HPP1, qMSP, NELL1, TAC1, AKAP12, CDH13, SST</_3:bmName>
    <_3:dataSharingPlan>Data to be shared via EDRN&amp;#39;s Data and Archive Service (EDRN) and made publicly available upon review and approval.</_3:dataSharingPlan>
    <_3:eligibilityCriteria>100 cases and 200 controls will be selected based on retrospective chart review of endoscopic
and pathology reports demonstrating BE, defined as salmon-colored mucosa in the tubular esophagus with intestinal metaplasia with goblet cells on biopsy. The endoscopic procedures were done as per routine clinical care at participating Consortia institutions. Cases are those BE patients who initially had either no or low grade
dysplasia, who eventually progressed to have either HGD or EAC (progressors). Controls will include patients with BE who have not progressed beyond low grade dysplasia (non-progressors).
</_3:eligibilityCriteria>
    <_3:protocolType>Validation</_3:protocolType>
    <_4:description>We performed a multicenter, couble-blinded validation study of 8 BE progression prediction methylation biomarkers.  Progression or nonprogression was determined at 2 years and 4 years.  Methylation was assayed in 145 nonprogressors (NPs) and 50 progressors(Ps) using real-time quantitative methylation-specific PCR.</_4:description>
    <_3:blinding>All samples were analyzed in a blinded fashion</_3:blinding>
    <_3:aims>Our specific aims include:
1. Utilizing methylation-specific PCR and FISH, to identify DNA methylation abnormalities and
chromosomal aberrancies which represent biomarkers of risk for progression to EAC in the setting of BE.
2. To perform multivariate analysis of the risk of progression to HGD or esophageal denocarcinoma in patients with methylation and FISH abnormalities after controlling for other known risk factors for EAC</_3:aims>
    <_3:outcome>A methylation biomarker-based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/348"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/343"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/344"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/347"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/345"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/346"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Other</_3:design>
    <_4:title>Barrett&amp;#39;s Esophagus Methylation Profiles</_4:title>
    <_3:objective>We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus (&amp;quot;progressors&amp;quot;), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC (&amp;quot;non-progressors&amp;quot;). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful  application for a prospective study of markers identified in this case-control study.</_3:objective>
    <_3:cancerType>150                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/245">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/193"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia</_3:abbreviatedName>
    <_4:title>Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153, 154                                                                                            </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>500 training set specimens, 750 test set speciments from patients deemed to be ?average risk? who are undergoing colonoscopy for colorectal cancer (CRC) screening or symptomatic indications.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/233">
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:objective>We hypothesize that PTMs on proteins that are secreted by the breast will provide a more sensitive method for detecting breast cancer than analysis of the parent protein.  We will antibody microarrays to have examine 9 circulating proteins, each of which is known to be actively secreted by the breast, for several structurally and functionally distinct PTMs.  We will  determine if these modified proteins have the potential to used in the early detection of breast cancer.</_3:objective>
    <_3:design>Case/control</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/233"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>PTM Microarray</_3:abbreviatedName>
    <_3:startDate>Dec 31 2007 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:estimatedFinishDate>Dec 30 2008 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>Post-translation modification for nitro-tyrosine and lipid peroxidation adducts on proteins secreted by the breast.</_3:bmName>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:blinding>The samples used for discovery will not be blinded.  Subsequent validation studies will use blinded samples.</_3:blinding>
    <_3:aims>Aim 1)  Develop antibody microarray chips that can be used to measure PTMs associated with glycosylation state or nTyr- or HNE-adducts.  This chip will target abundant proteins we have identified in NAF that are also found in the circulation.  

Aim 2)  Evaluate two sets of human plasma samples from women with and without breast cancer using the chips developed in Aim 1.  The first set of samples is from the Clinical Breast Care Program (CBCP, samples collected at Walter Reed Army Medical Center) and contains 80 samples from control women or women with DCIS or stage 1 or 2 breast cancer.  This set of samples will determine if these assays can detect early disease.  The second set of samples will be from Dr. Jeff Marks (Duke University) and will contain 60 samples evenly split between three study groups: control women and women with Her2+/ER- tumor, and women with ER+/Her2- breast cancer.  This set of samples will determine if these assays can detect both early- and late-stage disease as well as differentiate between different subtypes of cancer.
</_3:aims>
    <_3:analyticMethod>ELISA microarray</_3:analyticMethod>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_4:title>PTM Microarray: Request for Year 3 Set-Aside Funds</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>80 control samples (healthy, DCIS, or women with stage 1 or 2 breast cancer)
20 controls
20 samples from women with Her2+/ER- cancer
20 samples from women with ER+/Her2- cancer</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/232">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/201"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer</_3:abbreviatedName>
    <_3:startDate>Apr  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Mar 31 2010 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_4:title>Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>100 healthy individuals
100 participants with benign urinary tract pathology
100 participants with cystoscopically and pathologically verified TCC of the bladder
300 participants with a history of non-muscle invasive TCC bladder cancer</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/69">
    <_3:design>Convenience</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_4:title>Presence of simian virus 40 DNA sequences in human</_4:title>
    <_3:abbreviatedName>Presence of simian virus 40 DNA sequences in human</_3:abbreviatedName>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_4:description>Lymphoma specimens were collected and analyzed for the presence of SV40 sequences. The DMCC analyzed data for Adi Gazdar</_4:description>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/83">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:finishDate>May 26 2008 12:00AM</_3:finishDate>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_4:description>BACKGROUND: No proven ovarian cancer (OC) screening strategy exists for women who are at increased risk for the disease.  A risk of ovarian cancer algorithm (ROCA) using serial CA125 values have previously shown greater positive predictive value (PPV) and sensitivity than a single CA125 in screening women at general population risk.  We hypothesized that using ROCA would yield a reasonable PPV for ovarian cancer screening in a cohort at increased risk. METHODS: Between 7/2001 and 9/2006, 25 sites (14 CGN, 3 ovarian SPOREs, 1 EDRN, 7 others) prospectively enrolled patients. Inclusion criteria included: among self, 1st degree and 2nd degree relatives in same lineage either (i) BRCA 1/2 mutation, or (ii) two of OC or early onset (age &amp;#060; or = 50) breast cancer (BC), or (iii) Ashkenazi ethnicity and 1 of OC or BC.  A previous diagnosis of OC excluded subjects. Subjects underwent CA125 every 3 months and the risk of having ovarian cancer based on the CA125 profile was recalculated after each test. ROCA referred subjects with risk &amp;#062; 1% to ultrasound (US) and risk &amp;#062; 10% additionally to a gynecologic oncologist. Objectives included PPV for study indicated surgery, sensitivity, and compliance. Sample size was chosen to observe 8 OC endpoints with a power of 80% to rule out PPV &amp;#060; or = 10% if the true PPV = 20%.</_4:description>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Ovarian Cancer Screening Pilot Trial In High Risk Women</_3:abbreviatedName>
    <_4:title>Ovarian Cancer Screening Pilot Trial In High Risk Women</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:finalSampleSize>From Creighton University:
247 serum samples for CA-125 testing
247 serum samples and purple top tubes for biorepository for retrospective evaluation of other promising biomarkers.</_3:finalSampleSize>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:objective>This screening study includes women with high quantified risk of having a BRCA1/2 mutation, as well as women with a confirmed BRCA1/2 mutation.  This trial permits initial estimation of the incidence of ovarian cancer by age and menopausal status.  Subjects were screened for a minimum of one year and followed for up to one year.  Estimates of CA-125 values over time would provide the basis for refining the &amp;quot;risk of ovarian cancer algorithm&amp;quot; (ROCA) more accurately to high risk women and provide guidance for clinical interpretation of CA-125 tests in sub-groups (pre/post menopausal status, estrogen replacement therapy Y/N, and prophylactic oophorecomty Y/N).  </_3:objective>
    <_3:aims>To bring EDRN participation into the CGN study of early detection of ovarian cancer in high risk women using serum and plasma markers.   This is a project with Stephen Skates, Ph.D. (Massachusetts General Hospital, MGH Biostatistics Center) ?Ovarian cancer screening pilot trial in high risk women?.   We will recruit 30 women for this trial.</_3:aims>
    <_3:outcome>2,343 high risk women enrolled, with 6,284 women years of screening and 19,549 CA125s obtained.  There were 628 (10%/yr)referrals to ultrasound (US) with 414 US performed.  38 women underwent study indicated surgeries. 9 OCs were identified during screening, 3 were prevalent (1 early, 2 late stage),and 6 were incident (5/6 = 83% early, 1 late).  3 of the 6 incident cases were found on prophylctic oophorectomy in early stage.  ROCA deteted 2 in early stage of remaining 3 incident cases, and 3 of 3 prevalent cases.  The PPV was 5/38 = 13% (95% CI 4.4%, 28%) and sensitivity was 5/6 = 83%, CI (36%, 99%). There was high compliance with CA125 testing throughout the study, with 84%, 85%, 85%, 82% subjects returning within 1 month of schedule for 4 tests.  CONCLUSION: Frequent CA125 testing using ROCA results in an acceptable PPV and high compliance in a cohort of women at increased risk for OC.  A definitive screening study (&amp;#062; or = 30 incident cases) using ROCA with serial CA125 and possibly additional markers is required to define sensitivity for early stage OC.</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:bmName>CA125</_3:bmName>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/78">
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Molecular Basis of Barrett&amp;#39;s Associated Neoplasia</_3:abbreviatedName>
    <_4:title>Molecular Basis of Barrett&amp;#39;s Associated Neoplasia</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>150                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/82"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/100">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Andogenic Activity and the Association with Ovarian Cancer</_3:abbreviatedName>
    <_4:title>Andogenic Activity and the Association with Ovarian Cancer</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>183                                                                                                 </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/77"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/56">
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/68"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:design>Prospective</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Early Detection of Urinary Bladder Cancer</_3:abbreviatedName>
    <_4:title>Early Detection of Urinary Bladder Cancer</_4:title>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>188                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/71"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/66">
    <_3:collaborativeGroupText> </_3:collaborativeGroupText>
    <_3:design>Other</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>EDRN Informatics Pilot Project</_3:abbreviatedName>
    <_4:title>EDRN Informatics Pilot Project</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>                                                                                                    </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/115">
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:eligibilityCriteria>REFERENCE SETS A and C:

5.1 Clinical setting: Diagnosis of lung cancer

5.2 Cases eligibility Set A:

- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

- Blood collected prior to treatment (chemo/radiation)

5.3 Controls eligibility Set A
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an ?other cancer? control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status, and PKY history of smoking

5.4 Sample sizes Set A
(1) Rapid single biomarker pre-validation: 87 cases and 50 controls, 25 other cancer controls
(2) Panel of biomarkers pre-validation:150 cases and 150 controls
(3) Phase II validation:180 cases and 180 controls, 75 other cancer controls

5.5 Institution provider candidates Set A
Pittsburgh
Vanderbilt
MDACC
UCLA
UCHSC
NYU
JHU
 
REFERENCE SET B:

5.6 Clinical setting Set B
CT screening trial for the early detection of lung cancer

5.7 Cases eligib</_3:eligibilityCriteria>
    <_3:design>Other</_3:design>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/279"/>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/280"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/248"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/241"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/73"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/247"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/239"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/85"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/84"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/240"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/89"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/65"/>
    <_4:description>The Lung Cancer Biomarkers Group (LCBG) consists of scientists from the Early Detection Research Network (EDRN), Lung Cancer Specialized Programs of Research Excellence (SPOREs), the NCI and several other researchers. The objectives of the LCBG are to formulate specimen reference sets to be used for testing biomarkers for early detection or diagnosis of lung cancer. At present four reference sets have been planned using serum and plasma samples. The first two reference sets (A and B) are retrospective where select clinically annotated samples currently stored in freezers are provided by six institutions around the country. Collection of two additional reference set (C) is currently in preparation to be collected prospectively from six institutions. Sets A and C (180 cases &amp;#062; 50% Stage I, 180 controls, 75 other cancers) will focus on prevalidation of biomarkers for the diagnosis of lung cancer from patients with an abnormal chest X-ray or at high risk for lung cancer. Set B (170 cases, 250 controls) will focus on prevalidation of biomarkers for early detection of lung cancer in the context of computed-tomography (CT) screening of high risk individuals. Patients presenting with suspicious nodules between 0.5 ? 3 cm on CT-screening are required for inclusion in set B. All sets will be subdivided into a smaller rapid prevalidation subsets of individual biomarkers, whereas the full sets are required for prevalidation of multi biomarker panels or full validation. These reference sets will be assembled and stored at the NCI facility in Frederick, MD. Any investigator studying promising lung cancer biomarkers can request access to these sets pending approval of your application by an internal review committee within the LCBG</_4:description>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer.  Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.  

</_3:objective>
    <_4:title>Standard Specimen Reference Set:  Lung</_4:title>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:finalSampleSize>Set A:  180 Cases, 180 High Risk Controls &amp; 75 Other Cancers.
Set B: 170 Cases, 250 High Risk Controls and 75 Other Cancers.
Set C:  179 Cases, 181 High Risk Controls and 37 Other Cancers.</_3:finalSampleSize>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>LUNG-REF</_3:abbreviatedName>
    <_3:aims>Our specific goals include:
1.Develop reference case/control serum/plasma sets held in a NCI repository and make these samples available to the research community.
2.Define, refine and validate blood-based biomarkers for lung cancer.
3.Test reproducibility of biomarkers within and across institutions.
4.Test reproducibility of biomarkers within and across analytical platforms.
</_3:aims>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:dataSharingPlan>recipients of the specimens will sign a data sharing agreement</_3:dataSharingPlan>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/81">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:design>Convenience</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Methylation tumor markers in HNPCC</_3:abbreviatedName>
    <_4:title>Methylation tumor markers in HNPCC</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/257">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/75"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Prognostic Markers in Lynch Syndrome Colorectal Cancers</_3:abbreviatedName>
    <_3:startDate>Jul  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>153, 154                                                                                            </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/80"/>
    <_4:title>Prognostic Markers in Lynch Syndrome Colorectal Cancers</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/286">
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>see reference set</_3:finalSampleSize>
    <_3:dataSharingPlan>share according to EDRN guidelines</_3:dataSharingPlan>
    <_3:secureOutcome>No differences were detected between cases and controls, and therefore the marker was not validated</_3:secureOutcome>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/161"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Antibody microarray</_3:analyticMethod>
    <_3:abbreviatedName>Prostate Rapid Ref Set: Haab (2006)</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Feb  7 2007 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>TSP-1</_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>Refer to reference set</_3:eligibilityCriteria>
    <_3:startDate>Feb  1 2006 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>The performance of TSP-1 as a predictor of prostate cancer was evaluated in the EDRN Prostate Rapid Reference Set.  The TSP performance was measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (&amp;#060;7) and 30 had high Gleason grade (&amp;#062;=7).  No differences were detected between cases and controls, and therefore the marker was not validated</_4:description>
    <_3:blinding>yes</_3:blinding>
    <_3:aims>To evaluate TSP-1 as a marker to specifically detect prostate cancer using anitbody microarray technology</_3:aims>
    <_3:outcome>No differences were detected between cases and controls, and therefore the marker was not validated</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/161"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Prostate Rapid Reference Set Application:  Haab - Van Andel (2006)</_4:title>
    <_3:objective>To evaluate TSP-1 as a marker to specifically detect prostate cancer</_3:objective>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/134">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:eligibilityCriteria>3.2 Inclusion Criteria
3.2.1 Cases
Cases will include patients with HCC. Tumor staging will be performed using the modified TNM for HCC
used by UNOS. Early stage HCC is determined by the most recent CT or MRI that has lesion(s) and
maximum diameter. UNOS stage I (a single lesion &amp;#060; 2 cm) or stage II (single lesion between 2-&amp;#060;5 cm or
2-3 lesions each &amp;#060; 3 cm), with no vascular invasion (portal vein thrombosis) or extrahepatic metastasis.
Eligibility criteria for cases are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis HCC based on one of the following:
&amp;#1048707; Histology (required if only one lesion &amp;#060; 2 cm is present) ? Must have CT/MRI to calculate
stage
&amp;#1048707; Two imaging tests, with at least one (CT/MRI/Angiography) within the past 3 months or up to
2 weeks after consent showing evidence of arterial hypervascularization, and the other within
the past 6 months (US, CT, MRI/Angiography) indicating a mass in the liver.
&amp;#149; MELD &amp;#060; 15. If MELD &amp;#062;15, but INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of
intrinsic renal disease, then eligible.
&amp;#149; Lab results (other than AFP) must be within the past 90 days. AFP results are optional.
&amp;#149; Able and willing to provide written informed consent
The diagnostic criteria requiring two imaging tests in absence of a biopsy are based on an HCC Consensus
Conference (8). While it is preferable to use histologic confirmation of HCC to determine eligibility, it is
recognized that biopsies are not commonly done in patients with suspected HCC because of concerns of
complications; histology will only be required for patients with only one lesion present that is less than 2
cm.
3.2.2 Controls
Eligibility criteria for controls are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis of cirrhosis based on liver histology. In the absence of histology, cirrhosis would be
defined by an ultrasound or CT scan showing a cirrhotic-appearing liver with splenomegaly and
platelet count of &amp;#060; 120 mm-3. If there is no splenomegaly (or absent) or a platelet count of &amp;#8805; 120
mm-3, the</_3:eligibilityCriteria>
    <_3:design>Case/control</_3:design>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/311"/>
    <_3:contributesSpecimensTo rdf:resource="http://edrn.nci.nih.gov/data/protocols/285"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/147"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/148"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/146"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/275"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/145"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/144"/>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/143"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>Utilize the remaining specimens collected under the DCP protocol to develop and validate markers for the early detection of HCC</_3:objective>
    <_4:title>Standard Specimen Reference Set:  Liver</_4:title>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:cancerType>155                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>LIVER-REF</_3:abbreviatedName>
    <_3:aims>Specific Aims
Aim 1: To determine the sensitivity and specificity of des-gamma carboxyprothrombin (DCP) for the
diagnosis of early hepatocellular carcinoma (HCC).
Aim 2: To compare the accuracy of DCP and Alpha-fetoprotein (AFP) for the diagnosis of early HCC.
Aim 3: To determine whether demographic or etiology of underlying liver disease alter the expression of
DCP or AFP.</_3:aims>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:dataSharingPlan>recipients of the specimens will sign a data sharing agreement</_3:dataSharingPlan>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/231">
    <_3:collaborativeGroupText> </_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:design>Other</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/234"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>The purpose of this project is to develop antibody microarrays incorporating three major improvements compared to previous antibody microarray platforms, and to produce and disseminate these antibody microarray technologies for the Early Detection Research Network (EDRN) and the research community focusing on early detection, and risk assessment of cancer.</_3:objective>
    <_4:title>EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>                                                                                                    </_3:cancerType>
    <_3:fieldOfResearch>Other, Specify</_3:fieldOfResearch>
    <_3:aims>Stage I: A feasibility study ? comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls.   This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay.  The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM.

Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers.

In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/234"/>
    <_3:abbreviatedName>BRL: PNNL</_3:abbreviatedName>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/282">
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:dataSharingPlan>Make data available for all EDRN investigators. After publication, make data publicly available to scientific community.</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>FISH, qPCR, mass spectrometry, gene expression, ACGH, SNPS, methylation, microRNA</_3:analyticMethod>
    <_3:abbreviatedName>Canary Never Smokers</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Sep 15 2011 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>EGFR, KRAS, CpG, TITF1 </_3:bmName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:eligibilityCriteria>Ever smokers: person who has smoked &amp;#062;100 cigarettes during lifetime; Never Smokers: person who has smoked less than 100 cigarettes during lifetime; Current Smokers: person currently smoking who has quit for &amp;#062; one year; former smokers: smoker who has quit smoking for &amp;#062; one year; long-term former smokers: smoker who has quit smoking for &amp;#062; 10 years;
light smokers: smoker with total exposure of &amp;#062; 10 years.</_3:eligibilityCriteria>
    <_3:startDate>Sep 15 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:blinding>All specimens are blinded at the DMCC.</_3:blinding>
    <_3:aims>Specific aim 1: Identify biomarkers of potential use for early detection/risk assessment of lung cancers arising in never smokers.  Multiple platforms will be utilized by a team of highly experienced and competent investigators to compare and contrast the global and individual genetic alterations in lung cancers arising in current, former and never smokers. Appropriate samples or reagents from a set of already collected tumor and paired adjacent non-malignant lung tissues (or blood plasma) will be distributed to the investigators (Drs. Hanash, Gazdar, Lam and Sidransky). About 30 sets of samples from each group will be utilized.  Platforms to be studied will include serum proteomics (Hanash), global messenger gene expression (Gazdar), mutations and copy number analyses for a selected set of genes (Gazdar), global copy number alterations using both SNP and aCGH platforms (Lam) and mitochondrial mutations (Sidransky). Data will be collected and analyzed at the DMCC (Mark Thornquist) and at the Vancouver site (Wan Lam) which has developed software for integration and analysis of cross-platform data. Specific aim 2: Confirmation studies on biomarkers identified in Specific Aim 1. Promising markers identified in Specific Aim 1 will be verified in preclinical studies by other platforms such as FISH and immunostaining using tissue and cell line microarrays, Western blots and qPCR gene expression studies, functional assays etc. After completion of the phase one of the validation process, phase two studies will be initiated. Specific aim 3: Perform phase three validation studies. Markers identified by the DMCC as showing promise after completion of phase 2 studies will be proposed as candidates for EDRN supported phase 3 validation studies.</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/86"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/518"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/516"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/517"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/420"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/519"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/74"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/151"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Identification of biomarkers for lung cancer in never smokers</_4:title>
    <_3:objective>The overall goal of this project is to identify, verify and apply biomarkers for the early diagnosis or risk assessment of lung cancer in never smokers. The first year will be regarded as a year of discovery. After successful demonstration of the feasibility of the approach for novel marker discovery, funding will be applied for to perform confirmation and preclinical studies on
the biomarkers and validation studies (specific aims 2 and 3, to be performed in years two and three). Year two can be regarded as the year of confirmation and year three as the year of validation. </_3:objective>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>28 lifetime never smokers cases; 30 former smokers cases, 30 heavy current smokers cases, 30 smoker controls, 30 never smokers controls</_3:plannedSampleSize>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/53">
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/76"/>
    <_4:title>Proteomics Biomarker Development Laboratory</_4:title>
    <_3:abbreviatedName>Proteomics Biomarker Development Laboratory</_3:abbreviatedName>
    <_3:protocolType>Single</_3:protocolType>
    <_4:description>The Biomarker Development Laboratory is focused on the &amp;#060;br&amp;#062;application of a proteomic approach for the development&amp;#060;br&amp;#062; of cancer biomarkers.  The laboratory will apply &amp;#060;br&amp;#062;technologies for protein analysis to the detection and &amp;#060;br&amp;#062;identification of proteins secreted by tumor cells and &amp;#060;br&amp;#062;protein antigens that induce a humoral response in tumor&amp;#060;br&amp;#062;s.  The initial targeted tumor types for the identification&amp;#060;br&amp;#062; of potential biomarker proteins are:  Colon, esophagus,&amp;#060;br&amp;#062; ovary, lung, breast and liver.  The proposed studies will&amp;#060;br&amp;#062; make heavy utilization of two-dimensional (2-D) protein&amp;#060;br&amp;#062; analysis, of protein identification technologies and of &amp;#060;br&amp;#062;database capabilities that have been developed by the &amp;#060;br&amp;#062;applicant group.  The objectives of this research are &amp;#060;br&amp;#062;to 1.  Identify tumor antigens that induce a humoral &amp;#060;br&amp;#062;response; 2.  Identify tumor secreted proteins and develop&amp;#060;br&amp;#062;a database; 3.  Preliminarily validate the potential utility&amp;#060;br&amp;#062;of markers for early cancer detection.  Sixty ml of blood&amp;#060;br&amp;#062;will be obtained from healthy normals, and from small &amp;#060;br&amp;#062;cell lung cancer, hepatoma, esophageal, and breast cancer&amp;#060;br&amp;#062;patients, and from ovarian, colon, and non-small cell lung&amp;#060;br&amp;#062;cancer patients prior to surgical resection and six to&amp;#060;br&amp;#062;ten weeks after resection.  Demographic data, sera and &amp;#060;br&amp;#062;DNA will be used in 2-D protein analysis to identify new&amp;#060;br&amp;#062;or altered proteins.  The initial validation will be the &amp;#060;br&amp;#062;assay of the presence or absence of a given protein in a&amp;#060;br&amp;#062;large sample cohort from the samples collected from these&amp;#060;br&amp;#062;patients.  There is no specified age range, although the &amp;#060;br&amp;#062;diseases under study do not occur in children.  No subjects&amp;#060;br&amp;#062;will be excluded on the basis of race or gender.  Women&amp;#060;br&amp;#062;of child bearing age will be studied.  Linkable demographic&amp;#060;br&amp;#062;data will be held separately from the bar-coded serum or&amp;#060;br&amp;#062;DNA samples.  Serum and DNA sample will be identifiable&amp;#060;br&amp;#062;only by subject identification number.  Full written &amp;#060;br&amp;#062;informed consent will be obtained from patients.</_4:description>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/76"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/121">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:eligibilityCriteria>3 Subject Selection
3.1 Eligibility Criteria
3.1.1 Cases (n=300 invasive cancer and 100 DCIS: Up to 100 LCIS and 100 Pagets may
be included but are not the targeted population) and Benign Disease Controls (n=100 benign
non-proliferative conditions and 100 benign proliferative conditions)
a. Female
b. At least 18 years of age
c. Mammographic finding or palpable breast mass
d. Undergoing initial diagnosis to determine if breast cancer is present
3.1.2 Normal Controls (n=100):
a. Female
b. At least 18 years of age
c. Undergoing routine mammographic screening (with or without clinical breast
exam)
d. BIRADS score less than or equal to 2
3.2 Exclusion Criteria
3.2.1 Cases and Benign Disease Controls
a. Already diagnosed by biopsy for current presentation of breast cancer or benign
disease
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Recurrence of previous breast cancer
d. Pregnant or nursing
The consenting process and blood draw will be carried out before primary pathology results
are obtained. This may occur either before or after the diagnostic biopsy, but will be limited
to the same day that the biopsy is performed or up to 2 weeks prior to biopsy. There are two
reasons for this restriction: 1) It will ensure that the cancer (or benign) mass is present at the
time of blood sampling and 2) It will reduce potential biases that might result from subjects
knowing their diagnosis with certainty to be malignant or benign. No exclusion will be
made based upon age, race, extent of disease, drug usage, family history, prior biopsies, prior
benign diseases or prior DCIS.
3.2.2 Normal Controls
a. Current evidence of breast abnormality (prior benign disease or DCIS
acceptable)
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Pregnant or nursing
d. BIRADS score greater than 2 or palpable mass
For the purpose of this study, we defin</_3:eligibilityCriteria>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Prospective</_3:design>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>The primary objective of this study is to assemble a well-characterized set of blood specimens to
test biomarkers that, in conjunction with mammography, can detect and discriminate breast
cancer. These samples will be divided to provide ?sets? of specimens that can be tested in a
number of different laboratories. Since tests will be performed on the same sets of samples, the
data will be directly comparable and decisions regarding which biomarker or set of biomarkers
have value in breast cancer detection can be made. These sets will reside at a National Cancer
Institute facility at Frederick, MD.</_3:objective>
    <_4:title>Standard Specimen Reference Set:  Breast</_4:title>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/230"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/202"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/81"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/189"/>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>BREAST-REF</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:dataSharingPlan>recipients of the reference set sign a data sharing agreement</_3:dataSharingPlan>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/284">
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/521"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/200"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:collaborativeGroupText>Prostate and Urologic Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/127"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:abbreviatedName>Prostate Rapid Reference Set: Chan/Beckman (2007)</_3:abbreviatedName>
    <_3:phasedStatus>1</_3:phasedStatus>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>185                                                                                                 </_3:cancerType>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_4:title>Prostate Rapid Reference Set Application: Chan/Beckman Coulter (2007)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>rapid prostate reference set</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/251">
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:design>Case/control</_3:design>
    <_3:dataSharingPlan>recipients of the specimens will sign a data sharing agreement</_3:dataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/67"/>
    <_3:projectFlag>Project</_3:projectFlag>
    <_3:objective>The Early Detection Research Network, Great Lakes-New England Clinical,
Epidemiological and Validation Center (GLNE CVC) announces the availability of
serum, plasma and urine samples for the early detection for colon cancer and validation
studies.</_3:objective>
    <_4:title>Standard Specimen Refernce Set: Colon</_4:title>
    <_3:protocolType>Reference Set</_3:protocolType>
    <_3:finalSampleSize>The reference set consists of replicate aliquots from 50 subjects with colorectal
adenocarcinoma, 50 subjects with adenomas confirmed by pathology, and 50 subject with
normal colons after colonoscopy. Normals selected for the reference set did not have
polyps of any kind found on colonoscopy.</_3:finalSampleSize>
    <_3:cancerType>153                                                                                                 </_3:cancerType>
    <_3:abbreviatedName>COLON-REF</_3:abbreviatedName>
    <_3:aims>Two prospective studies were used to collect samples to make this
reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and
Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical
trial to collect serum, plasma, urine, and common data elements on subjects undergoing
routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon
cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of
Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to
collect serum, plasma, urine, stool, and common data elements. In both protocols,
subjects were undergoing routine colonoscopy (or being seen in surgery clinic for
colorectal cancer) when the samples were collected. Samples were collected while the
target lesions were still in place in the colon. Subjects were either normal (without
adenomas or cancer), with pathologically confirmed adenomas or pathologically
confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included
known hepatitis C or HIV, ulcerative colitis, Crohns?s Disease or IBD, history of cancer
within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were
collected from 4 sites around North America.</_3:aims>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:plannedSampleSize>Serum from 50 normal, 50 adenoma, and 50 CRC.
Plasma from 50 normal, 50 adenoma, and 50 CRC.
Urine from 50 normal, 50 adenoma, and 50 CRC.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/106">
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:design>Case/control</_3:design>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>pre-operative plevic mass study</_3:abbreviatedName>
    <_4:title>pre-operative plevic mass study</_4:title>
    <_3:protocolType>Single</_3:protocolType>
    <_3:cancerType>180, 183                                                                                            </_3:cancerType>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/70"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/314">
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:fieldOfResearch>Genomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
    <_3:fieldOfResearch>Metabolomics</_3:fieldOfResearch>
    <_3:secureOutcome>Combined parameter &amp;#060;homocysteine (Hcy) level and comet distribution&amp;#062; is proposed as advanced biomarker for predictive breast cancer diagnosis in peri- and post-menopausal women after 45 years of age</_3:secureOutcome>
    <_3:collaborativeGroupText>Breast and Gynecologic Cancers Research</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/579"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>Measurements of Homocysteine in blood-plasma
Measurements of homocysteine in EDTA-plasma were performed using high performance liquid chromatography (HPLC) as described elsewhere.

Comet Assay analysis
The ?Comet assay? provides a simple and effective method for evaluation of DNA damage and DNA-repair capacity in single cells such as leukocytes. The principle of the assay is based upon the ability of DNA fragments to migrate out of the cell under the influence of an electric field. An evaluation of the ?comet? tail shape and DNA fragments migration pattern allows for assessment of DNA damage and repair capacity. </_3:analyticMethod>
    <_3:estimatedFinishDate>Dec  1 2009 12:00AM</_3:estimatedFinishDate>
    <_3:objective>Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality caused by breast cancer. However, besides negative short-term effects (blood flow disturbances, painful erythema, etc.) breast irradiation causes severe long-term side-effects (leucopenia, anemia, breast edema, fibrosis, increase of angiosarcoma, leukemia, myelodysplastic syndromes). Therefore, the identification of individual susceptibility to radiation and improved patient-specific radiotherapy planning are highly desirable for personalised treatment in breast cancer. 
Why early and predictive diagnosis is crucial for long-term outcomes of breast cancer?
 Breast cancer is the most common cause of cancer death among women with an average incidence rate of 10-12 per 100 women. In 2005, breast cancer led to 502,000 deaths worldwide. Advanced stages of breast cancer lead to the development of metastasis predominantly in the lymph nodes, bone, lung, skin, brain, and liver. Although breast-MRI is currently the most sensitive diagnostic tool for breast imaging, its specificity is limited resulting in a negative impact for surgical management in approximately 9 % of cases. Early diagnosis has been demonstrated to be highly beneficial, enabling significantly enhanced therapy efficiency and possibly full recovery.
</_3:objective>
    <_3:bmName>- Ex vivo sub-cellular imaging of DNA-damage and -repair in circulating leukocytes
- Homocystein level in blood-plasma
- Pathology-specific protein-profiles in circulating leukocytes
</_3:bmName>
    <_3:eligibilityCriteria>Inclusion criteria:
- benign breast pathologies, 
- all types of breast malignancy, 
- pre/peri/post-menopausal status, 
- familial/genetic predisposition

exclusion criteria:
-Pregnancy, 
-Breast-feeding, 
-alcohol and drug abuse.

</_3:eligibilityCriteria>
    <_3:startDate>Jan  1 2005 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:blinding>Patient&amp;#39;s data have been encoded.  Both-lab analysis and clinical correlation analysis-have been performed according to the double-blind principle.</_3:blinding>
    <_3:aims>Some recently developed, advanced diagnostic approaches focus on minimally invasive blood analysis as a valuable source of information concerning individual stress reactions under irradiation treatment. The prognostic role of leukocyte activity in breast cancer patients has long been recognised. Although fluctuating considerably among both node- negative and -positive patients, this activity has been demonstrated to be significantly lower in patients with a greater tumour burden. The authors emphasise the necessity for a more comprehensive analysis that would consider late effects of radiotherapy, stress-response and repair kinetics in terms of diagnostic and prognostic purposes in favour of the personalised treatment of breast cancer patients.

In addition to the increased risk of tumour-spreading by invasive biopsies, a serious disadvantage of utilizing biopsy samples for molecular imaging is the mixed cell population obtained, strongly varying from case to case, and resulting in differential gene expression with limited specificity related to the pathology. 

The central concept of our research in favour to non-invasive diagnosis focuses on 
1. blood-tests for the prediction of an individual?s predisposition,
2. highly homogeneous subgroups considering single criteria of  patients grouping such as age, familial/genetic predisposition, benign breast pathologies versus malignancy, pre/peri/post-menopausal status, accompanying diseases (e.g. metabolic disorder), etc.
3. combined biomarkers to increase the predictive power of the diagnostic approach.
</_3:aims>
    <_3:outcome>Combined parameter &amp;#060;homocysteine (Hcy) level and comet distribution&amp;#062; is proposed as advanced biomarker for predictive breast cancer diagnosis in peri- and post-menopausal women after 45 years of age</_3:outcome>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/579"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Case/control</_3:design>
    <_4:title>Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment</_4:title>
    <_3:abbreviatedName>Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized</_3:abbreviatedName>
    <_3:cancerType>174                                                                                                 </_3:cancerType>
    <_3:plannedSampleSize>From the current pool of patients treated at the ?Centre of Excellence for Brest Cancer Research?, Friedrich-Wilhelms-University of Bonn, 110 patients were recruited for this multidisciplinary study. According to the diagnosis, the recruited patients were grouped as follows: pre-menopausal women with benign alterations in breast tissue (G1); post-menopausal women with benign alterations in breast tissue (G2); invasive lobular &amp; ductal carcinomas in pre-menopausal women (G3); invasive lobular &amp; ductal carcinomas in post-menopausal women (G4); all of them - equally distributed among 4 subgroups.</_3:plannedSampleSize>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/234">
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/191"/>
    <_3:collaborativeGroupText>G.I. and Other Associated Cancers Research Group</_3:collaborativeGroupText>
    <_3:inSituDataSharingPlan>No</_3:inSituDataSharingPlan>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:abbreviatedName>Pancreatic Cancer Early Detection Stem Cell Biomarkers</_3:abbreviatedName>
    <_3:startDate>Jul  1 2008 12:00AM</_3:startDate>
    <_3:protocolType>Collaboration</_3:protocolType>
    <_3:cancerType>157                                                                                                 </_3:cancerType>
    <_3:estimatedFinishDate>Jun 30 2009 12:00AM</_3:estimatedFinishDate>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/167"/>
    <_4:title>Pancreatic Cancer Early Detection Stem Cell Biomarkers (CA117452 Set-Aside)</_4:title>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://edrn.nci.nih.gov/data/protocols/317">
    <_3:obtainsSpecimensFrom rdf:resource="http://edrn.nci.nih.gov/data/protocols/115"/>
    <_3:inSituDataSharingPlan>Yes</_3:inSituDataSharingPlan>
    <_3:finalSampleSize>178 Lung Cancer Cases, 179 High Risk Controls and 37 other cancer controls</_3:finalSampleSize>
    <_3:dataSharingPlan>Per reference set receipt guidelines</_3:dataSharingPlan>
    <_3:collaborativeGroupText>Lung and Upper Aerodigestive Cancers Research Group</_3:collaborativeGroupText>
    <_3:leadInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/580"/>
    <_3:projectFlag>Protocol</_3:projectFlag>
    <_3:analyticMethod>This section describes SomaLogic?s statistical methods for biomarker discovery and classifier construction.  These methods were applied to the data presented above, and similar approaches will be used with the EDRN samples.  If our application is approved, the EDRN samples would be run on the SLaptamer array (approximately 800 analytes) and analysis completed by June 2009.  The samples would then be run on subsequent larger arrays as they are developed. SomaLogic has experienced bioinformatics and statistics experts on staff as well as clinical biostatistics consultants.  SomaLogic would nonetheless welcome an opportunity to collaborate with the extensive network of EDRN biostatisticians to learn new ways to identify and characterize potential biomarkers, and develop and optimize classifier algorithms for specific clinical applications.  

All sample information, including sample receipt, clinical data and assay data will be captured, linked and stored in the SomaLogic laboratory information management LIMS system. Statistical analysis will be conducted using parametric and non-parametric models constructed and implemented in java running in a windows environment. Back-ups of all project data are conducted daily, and all back-up data is stored both locally as well as at a SomaLogic redundant off-site location. 

There are two primary statistical problems to be solved in the proposed study: (i) identification of biomarkers that discriminate among the sample classes, and (ii) the construction of classifiers that allow for a new sample to be evaluated. The identification of statistically significant differential protein expression between the control samples and the disease samples will be performed using both parametric and nonparametric tests.  The Kolmogorov-Smirnov (K-S) test is a non-parametric test that can be applied to marker identification.  Similarly, Student?s t-test and an F-test can be used for marker discovery when data are normally distributed.  Several classification methods will be applied to the datasets, including a parametric Bayesian classification scheme, linear discriminate analysis, and a nearest-neighbor classification scheme.  The sample sets will be divided into train and test sets to assess the quality of the classifiers.  
</_3:analyticMethod>
    <_3:abbreviatedName>Lung C Reference Set (Full): SomaLogics (2010): Ostroff</_3:abbreviatedName>
    <_3:coordinatingInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:estimatedFinishDate>Aug  1 2010 12:00AM</_3:estimatedFinishDate>
    <_3:bmName>Final algorithm will include proteins from this list:
AMPM2, Apo A-I, b-ECGF, BLC, BMP-1, BTK, C1s, C9, Cadherin E, Cadherin-6, Calpain I, Catalase, CATC, Cathepsin H ,CD30 Ligand, CDK5-p35, CK-MB, CNDP1, Contactin-5, CSK, Cyclophilin A, Endostatin, ERBB1, FGF-17, FYN, GAPDH liver, HMG-1, HSP 90a, HSP 90b, IGFBP-2, IL-15 Ra, IL-17B, IMB1, Kallikrein 7, KPCI, LDH-H 1, LGMN, LRIG3, Macrophage mannose receptor, MEK1, METAP1, Midkine, MIP-5, MK13, MMP-7, NACA, NAGK, PARC, Proteinase-3, Prothrombin, PTN, RAC1, Renin, RGM-C, SCFsR, sL-Selectin, TCTP, UBE2N, Ubiquitin+1, VEGF, YES
</_3:bmName>
    <_3:eligibilityCriteria>Cases eligibility:
- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

- Blood collected prior to treatment (chemo/radiation)

Controls eligibility
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an ?other cancer? control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate) ? Set C only 37 other cancers.

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status, and PKY history of smoking
</_3:eligibilityCriteria>
    <_3:startDate>May  1 2010 12:00AM</_3:startDate>
    <_3:protocolType>Single</_3:protocolType>
    <_3:blinding>all samples were blinded by the DMCC</_3:blinding>
    <_3:aims>To use the EDRN lung biomarker serum set C to
1. Validate the biomarkers discovered in the train and verification studies
2. Refine the classifier for detection of lung cancer in individuals with indeterminant pulmonary nodules.

</_3:aims>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/87"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/580"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/5"/>
    <_3:involvedInvestigatorSite rdf:resource="http://edrn.nci.nih.gov/data/sites/131"/>
    <rdf:type rdf:resource="http://edrn.nci.nih.gov/rdf/types.rdf#Protocol"/>
    <_3:design>Prospective</_3:design>
    <_4:title>Lung C Reference Set (Full): Rachel Ostroff - SomaLogics (2010)</_4:title>
    <_3:objective>Analysis of the EDRN lung biomarker samples will enable the next step in development of a clinical diagnostic assay for the differential diagnosis of lung cancer or benign disease in patients with indeterminant pulmonary nodules.  The objective is to develop a blood test with sufficient accuracy to identify lung cancer in these patients, which will aid the treating physician in decisions to recommend invasive procedures or watchful waiting.</_3:objective>
    <_3:cancerType>162                                                                                                 </_3:cancerType>
    <_3:fieldOfResearch>Proteomics</_3:fieldOfResearch>
  </rdf:Description>
</rdf:RDF>
